1
|
Singer C, Egle D, Greil R, Öhler L, Petru E, Suppan C, Marhold M, Pfeiler G, Brunner C, Tinchon C, Halper S, Galid A, Pluschnig U, Haslbauer F, Hubalek M, Redl A, Flatschacher J, Hennebelle M, Mraz B, Bartsch R. 172P REACHAUT: Real-world study of first-line (1L) ribociclib (RIB) + endocrine therapy (ET) in HR+, HER2- metastatic breast cancer (MBC). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.03.272] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
2
|
Gampenrieder S, Rinnerthaler G, Petzer A, Tinchon C, Fuchs D, Balic M, Heibl S, Rumpold H, Egle D, Zabernigg A, Singer C, Andel J, Hubalek M, Knauer M, Greil R. Impact of pertuzumab and T-DM1 on prognosis of HER2-positive metastatic breast cancer (MBC) and factors affecting their efficacy: Results from the AGMT_MBC-registry. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz242.046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
3
|
Bjelic-Radisic V, Singer C, Pfeiler G, Hubalek M, Bartsch R, Stöger H, Pichler A, Petru E, Greil R, Wette V, Petzer A, Sevelda P, Egle D, Dubsky P, Fitzal F, Jakesz R, Balic M, Frantal S, Sölkner L, Gnant M. Quality-of-life results from a randomized, phase-II-study of the therapeutic cancer vaccine L-BLP25 (Stimuvax®) in the preoperative treatment of women with primary breast cancer (ABCSG-34). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx362.059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
4
|
Oberguggenberger A, Meraner V, Sztankay M, Beer B, Weigel G, Oberacher H, Kemmler G, Czech T, Holzner B, Wildt L, Sperner-Unterweger B, Daniaux M, Hubalek M. Can we use gonadotropin plasma concentration as surrogate marker for BMI-related incomplete estrogen suppression in breast cancer patients receiving anastrozole? BMC Cancer 2017; 17:226. [PMID: 28351392 PMCID: PMC5371265 DOI: 10.1186/s12885-017-3208-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2016] [Accepted: 03/21/2017] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND BMI has been suggested to impact on estrogenic activity in patients receiving anastrozole resulting in a reduced treatment efficacy in obese women. Current evidence in this regard is controversially discussed. Since estradiol is inversely correlated with gonadotropins it can be assumed that an impact of BMI is also reflected by gonadotropin plasma concentrations. We aim at investigating the impact of BMI on the hormonal state of breast cancer (BC) patients receiving anastrozole indicated by LH, FSH and SHBG as well as estradiol. METHODS We determined gonadotropin-, estradiol- and anastrozole- serum concentrations from postmenopausal, early stage breast cancer patients receiving upfront anastrozole within routine after care. Gonadotropin plasma concentrations were derived from the routine laboratory examination report. A liquid chromatography tandem mass spectrometry method was used for the measurement of anastrozole serum concentrations. BMI was assessed within the routine after-care check-up. RESULTS The overall sample comprised 135 BC patients with a mean age of 65.3 years. BMI was significantly correlated with LH, FSH and SHBG. This association was neither influenced by age nor by anastrozole serum concentrations according to the regression model. Despite aromatase inhibition 12% of patients had detectable estrogen levels in routine quantification. CONCLUSION Obese women have an altered hormonal situation compared to normally weight women under the same dose of anastrozole. Our study findings are a further indicator for the relevance of BMI in regard of anastrozole metabolism and possible estrogenic activity indicated by gonadotropin plasma level.
Collapse
Affiliation(s)
- A Oberguggenberger
- Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University of Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria
| | - V Meraner
- Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University of Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria
| | - M Sztankay
- Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University of Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria
| | - B Beer
- Institute of Legal Medicine and Core Facility Metabolomics, Innsbruck Medical University, Muellerstrasse 44, 6020, Innsbruck, Austria
| | - G Weigel
- Central Institute for Medical and Chemical Laboratory Diagnostics, Innsbruck Medical University, Anichstrasse 35, 6020, Innsbruck, Austria
| | - H Oberacher
- Institute of Legal Medicine and Core Facility Metabolomics, Innsbruck Medical University, Muellerstrasse 44, 6020, Innsbruck, Austria
| | - G Kemmler
- Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University of Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria
| | - T Czech
- Department of Obstetrics and Gynecology, Innsbruck Medical University, Anichstraße 35, 6020, Innsbruck, Austria
| | - B Holzner
- Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University of Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria
| | - L Wildt
- Department of Gynecological Endocrinology and Reproductive Medicine, Innsbruck Medical University, Anichstrasse 35, 6020, Innsbruck, Austria
| | - B Sperner-Unterweger
- Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University of Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria
| | - M Daniaux
- Department of Radiology, Innsbruck Medical University, Anichstrasse 35, 6020, Innsbruck, Austria
| | - M Hubalek
- Department of Obstetrics and Gynecology, Innsbruck Medical University, Anichstraße 35, 6020, Innsbruck, Austria.
| |
Collapse
|
5
|
Singer CF, Pfeiler G, Hubalek M, Bartsch R, Stoeger H, Pichler A, Petru E, Greil R, Rudas M, Tea MKM, Wette V, Petzer AL, Sevelda P, Egle D, Dubsky PC, Balic M, Tinchon C, Bago-Horvath Z, Frantal S, Michael G. Abstract P6-10-01: Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomized, neoadjuvant phase-II study (ABCSG-34). Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p6-10-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Immune-based therapeutic strategies represent a promising approach in early and advanced breast cancer treatment. MUC1 glycoprotein is overexpressed and aberrantly glycosylated in over 90% of malignant breast cancer. It is involved in oncogenesis and confers resistance to anti-cancer therapies, thus representing a particularly promising target. Tecemotide is a MUC1-based therapeutic cancer vaccine. The aim of this trial was to investigate the efficacy and safety of preoperative tecemotide in primary breast cancer patients receiving neoadjuvant Standard-of-Care (SoC) treatment.
Patients and Methods: 400 patients with HER2-negative early breast cancer were recruited into this prospective, multicentre randomized 2-arm academic phase-II trial. Patients received preoperative SoC treatment with or without tecemotide therapy. Postmenopausal women with E+++, or E++ and Ki67 <14%, and G1,2,X tumors received 6 months of letrozole as SoC. Postmenopausal patients with triple-negative, E- or E+, or E++ and Ki67 ≥14%, and with G3 tumors, and all premenopausal patients received 4 cycles of epirubicin/cyclophosphamide plus 4 cycles of docetaxel as SoC. Patients were additionally randomized to receive reverse or conventional sequence of epirubicin/cyclophosphamide and docetaxel. Primary endpoint was histopathological response measured by Residual Cancer Burden (RCB0/I vs RCBII/III) at the time of surgery. Secondary endpoints included pCR, efficacy of reverse versus conventional sequence chemotherapy, and safety.
Results: We did not observe a significant difference in RCB0/I rates between patients with (36.4%) and without (31.9%) tecemotide in the overall study population (p = 0.40), and in endocrine and chemotherapy treated subgroups (25.0% vs 13.3%, p = 0.17; 39.6% vs 37.8%, p = 0.75). Similarly, addition of tecemotide did not affect overall pCR rates (22.5% vs 17.4%, p = 0.23). RCB0/I rates were comparable regardless of docetaxel being given before or after epirubicin/cyclophosphamide (37.2% vs 40.1%, p = 0.61). Tecemotide addition was not associated with a worse toxicity profile (178 AEs, 57 SAEs vs 180 AEs, 48 SAEs based on patient incidence).
Conclusion: Immune-based targeting of MUC1 by tecemotide is safe but does not improve RCB and pCR rates in early SoC-treated breast cancer.
Citation Format: Singer CF, Pfeiler G, Hubalek M, Bartsch R, Stoeger H, Pichler A, Petru E, Greil R, Rudas M, Tea M-KM, Wette V, Petzer AL, Sevelda P, Egle D, Dubsky PC, Balic M, Tinchon C, Bago-Horvath Z, Frantal S, Michael G. Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomized, neoadjuvant phase-II study (ABCSG-34) [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-10-01.
Collapse
Affiliation(s)
- CF Singer
- Medical University of Vienna, Vienna, Austria; Medical University of Innsbruck, Innsbruck, Austria; Medical University of Graz, Graz, Austria; Hospital Leoben, Leoben, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria; Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria; Breast Center/ Doctor's Office Wette, St. Veit an der Glan, Austria; Internal Medicine I/ Medical Oncology, Barmherzige Schwestern Hospital Linz, Linz, Austria; Hospital Hietzing, Vienna, Austria; Austrian Breast & Colorectal Cancer Study Group, Vienna, Austria
| | - G Pfeiler
- Medical University of Vienna, Vienna, Austria; Medical University of Innsbruck, Innsbruck, Austria; Medical University of Graz, Graz, Austria; Hospital Leoben, Leoben, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria; Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria; Breast Center/ Doctor's Office Wette, St. Veit an der Glan, Austria; Internal Medicine I/ Medical Oncology, Barmherzige Schwestern Hospital Linz, Linz, Austria; Hospital Hietzing, Vienna, Austria; Austrian Breast & Colorectal Cancer Study Group, Vienna, Austria
| | - M Hubalek
- Medical University of Vienna, Vienna, Austria; Medical University of Innsbruck, Innsbruck, Austria; Medical University of Graz, Graz, Austria; Hospital Leoben, Leoben, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria; Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria; Breast Center/ Doctor's Office Wette, St. Veit an der Glan, Austria; Internal Medicine I/ Medical Oncology, Barmherzige Schwestern Hospital Linz, Linz, Austria; Hospital Hietzing, Vienna, Austria; Austrian Breast & Colorectal Cancer Study Group, Vienna, Austria
| | - R Bartsch
- Medical University of Vienna, Vienna, Austria; Medical University of Innsbruck, Innsbruck, Austria; Medical University of Graz, Graz, Austria; Hospital Leoben, Leoben, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria; Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria; Breast Center/ Doctor's Office Wette, St. Veit an der Glan, Austria; Internal Medicine I/ Medical Oncology, Barmherzige Schwestern Hospital Linz, Linz, Austria; Hospital Hietzing, Vienna, Austria; Austrian Breast & Colorectal Cancer Study Group, Vienna, Austria
| | - H Stoeger
- Medical University of Vienna, Vienna, Austria; Medical University of Innsbruck, Innsbruck, Austria; Medical University of Graz, Graz, Austria; Hospital Leoben, Leoben, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria; Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria; Breast Center/ Doctor's Office Wette, St. Veit an der Glan, Austria; Internal Medicine I/ Medical Oncology, Barmherzige Schwestern Hospital Linz, Linz, Austria; Hospital Hietzing, Vienna, Austria; Austrian Breast & Colorectal Cancer Study Group, Vienna, Austria
| | - A Pichler
- Medical University of Vienna, Vienna, Austria; Medical University of Innsbruck, Innsbruck, Austria; Medical University of Graz, Graz, Austria; Hospital Leoben, Leoben, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria; Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria; Breast Center/ Doctor's Office Wette, St. Veit an der Glan, Austria; Internal Medicine I/ Medical Oncology, Barmherzige Schwestern Hospital Linz, Linz, Austria; Hospital Hietzing, Vienna, Austria; Austrian Breast & Colorectal Cancer Study Group, Vienna, Austria
| | - E Petru
- Medical University of Vienna, Vienna, Austria; Medical University of Innsbruck, Innsbruck, Austria; Medical University of Graz, Graz, Austria; Hospital Leoben, Leoben, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria; Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria; Breast Center/ Doctor's Office Wette, St. Veit an der Glan, Austria; Internal Medicine I/ Medical Oncology, Barmherzige Schwestern Hospital Linz, Linz, Austria; Hospital Hietzing, Vienna, Austria; Austrian Breast & Colorectal Cancer Study Group, Vienna, Austria
| | - R Greil
- Medical University of Vienna, Vienna, Austria; Medical University of Innsbruck, Innsbruck, Austria; Medical University of Graz, Graz, Austria; Hospital Leoben, Leoben, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria; Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria; Breast Center/ Doctor's Office Wette, St. Veit an der Glan, Austria; Internal Medicine I/ Medical Oncology, Barmherzige Schwestern Hospital Linz, Linz, Austria; Hospital Hietzing, Vienna, Austria; Austrian Breast & Colorectal Cancer Study Group, Vienna, Austria
| | - M Rudas
- Medical University of Vienna, Vienna, Austria; Medical University of Innsbruck, Innsbruck, Austria; Medical University of Graz, Graz, Austria; Hospital Leoben, Leoben, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria; Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria; Breast Center/ Doctor's Office Wette, St. Veit an der Glan, Austria; Internal Medicine I/ Medical Oncology, Barmherzige Schwestern Hospital Linz, Linz, Austria; Hospital Hietzing, Vienna, Austria; Austrian Breast & Colorectal Cancer Study Group, Vienna, Austria
| | - M-KM Tea
- Medical University of Vienna, Vienna, Austria; Medical University of Innsbruck, Innsbruck, Austria; Medical University of Graz, Graz, Austria; Hospital Leoben, Leoben, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria; Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria; Breast Center/ Doctor's Office Wette, St. Veit an der Glan, Austria; Internal Medicine I/ Medical Oncology, Barmherzige Schwestern Hospital Linz, Linz, Austria; Hospital Hietzing, Vienna, Austria; Austrian Breast & Colorectal Cancer Study Group, Vienna, Austria
| | - V Wette
- Medical University of Vienna, Vienna, Austria; Medical University of Innsbruck, Innsbruck, Austria; Medical University of Graz, Graz, Austria; Hospital Leoben, Leoben, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria; Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria; Breast Center/ Doctor's Office Wette, St. Veit an der Glan, Austria; Internal Medicine I/ Medical Oncology, Barmherzige Schwestern Hospital Linz, Linz, Austria; Hospital Hietzing, Vienna, Austria; Austrian Breast & Colorectal Cancer Study Group, Vienna, Austria
| | - AL Petzer
- Medical University of Vienna, Vienna, Austria; Medical University of Innsbruck, Innsbruck, Austria; Medical University of Graz, Graz, Austria; Hospital Leoben, Leoben, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria; Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria; Breast Center/ Doctor's Office Wette, St. Veit an der Glan, Austria; Internal Medicine I/ Medical Oncology, Barmherzige Schwestern Hospital Linz, Linz, Austria; Hospital Hietzing, Vienna, Austria; Austrian Breast & Colorectal Cancer Study Group, Vienna, Austria
| | - P Sevelda
- Medical University of Vienna, Vienna, Austria; Medical University of Innsbruck, Innsbruck, Austria; Medical University of Graz, Graz, Austria; Hospital Leoben, Leoben, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria; Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria; Breast Center/ Doctor's Office Wette, St. Veit an der Glan, Austria; Internal Medicine I/ Medical Oncology, Barmherzige Schwestern Hospital Linz, Linz, Austria; Hospital Hietzing, Vienna, Austria; Austrian Breast & Colorectal Cancer Study Group, Vienna, Austria
| | - D Egle
- Medical University of Vienna, Vienna, Austria; Medical University of Innsbruck, Innsbruck, Austria; Medical University of Graz, Graz, Austria; Hospital Leoben, Leoben, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria; Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria; Breast Center/ Doctor's Office Wette, St. Veit an der Glan, Austria; Internal Medicine I/ Medical Oncology, Barmherzige Schwestern Hospital Linz, Linz, Austria; Hospital Hietzing, Vienna, Austria; Austrian Breast & Colorectal Cancer Study Group, Vienna, Austria
| | - PC Dubsky
- Medical University of Vienna, Vienna, Austria; Medical University of Innsbruck, Innsbruck, Austria; Medical University of Graz, Graz, Austria; Hospital Leoben, Leoben, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria; Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria; Breast Center/ Doctor's Office Wette, St. Veit an der Glan, Austria; Internal Medicine I/ Medical Oncology, Barmherzige Schwestern Hospital Linz, Linz, Austria; Hospital Hietzing, Vienna, Austria; Austrian Breast & Colorectal Cancer Study Group, Vienna, Austria
| | - M Balic
- Medical University of Vienna, Vienna, Austria; Medical University of Innsbruck, Innsbruck, Austria; Medical University of Graz, Graz, Austria; Hospital Leoben, Leoben, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria; Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria; Breast Center/ Doctor's Office Wette, St. Veit an der Glan, Austria; Internal Medicine I/ Medical Oncology, Barmherzige Schwestern Hospital Linz, Linz, Austria; Hospital Hietzing, Vienna, Austria; Austrian Breast & Colorectal Cancer Study Group, Vienna, Austria
| | - C Tinchon
- Medical University of Vienna, Vienna, Austria; Medical University of Innsbruck, Innsbruck, Austria; Medical University of Graz, Graz, Austria; Hospital Leoben, Leoben, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria; Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria; Breast Center/ Doctor's Office Wette, St. Veit an der Glan, Austria; Internal Medicine I/ Medical Oncology, Barmherzige Schwestern Hospital Linz, Linz, Austria; Hospital Hietzing, Vienna, Austria; Austrian Breast & Colorectal Cancer Study Group, Vienna, Austria
| | - Z Bago-Horvath
- Medical University of Vienna, Vienna, Austria; Medical University of Innsbruck, Innsbruck, Austria; Medical University of Graz, Graz, Austria; Hospital Leoben, Leoben, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria; Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria; Breast Center/ Doctor's Office Wette, St. Veit an der Glan, Austria; Internal Medicine I/ Medical Oncology, Barmherzige Schwestern Hospital Linz, Linz, Austria; Hospital Hietzing, Vienna, Austria; Austrian Breast & Colorectal Cancer Study Group, Vienna, Austria
| | - S Frantal
- Medical University of Vienna, Vienna, Austria; Medical University of Innsbruck, Innsbruck, Austria; Medical University of Graz, Graz, Austria; Hospital Leoben, Leoben, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria; Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria; Breast Center/ Doctor's Office Wette, St. Veit an der Glan, Austria; Internal Medicine I/ Medical Oncology, Barmherzige Schwestern Hospital Linz, Linz, Austria; Hospital Hietzing, Vienna, Austria; Austrian Breast & Colorectal Cancer Study Group, Vienna, Austria
| | - G Michael
- Medical University of Vienna, Vienna, Austria; Medical University of Innsbruck, Innsbruck, Austria; Medical University of Graz, Graz, Austria; Hospital Leoben, Leoben, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria; Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria; Breast Center/ Doctor's Office Wette, St. Veit an der Glan, Austria; Internal Medicine I/ Medical Oncology, Barmherzige Schwestern Hospital Linz, Linz, Austria; Hospital Hietzing, Vienna, Austria; Austrian Breast & Colorectal Cancer Study Group, Vienna, Austria
| |
Collapse
|
6
|
Rinnerthaler G, Gampenrieder SP, Voskova D, Petzer A, Hubalek M, Petru E, Hartmann B, Andel J, Balic M, Melchardt T, Ulmer H, Mlineritsch B, Greil R. Abstract P5-15-13: Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Final PFS results of a phase II trial (AGMT MBC-6). Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-15-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Capecitabine is a well-established treatment option in HER2-negative advanced breast cancer (ABC) patients. Bendamustine is a generally well tolerated cytotoxic drug. Since bendamustine has already shown anticancer activity in ABC we evaluated the efficacy and tolerability of bendamustine in combination with capecitabine in pretreated patients with ABC. Here we present the final PFS results of this phase II trial.
Patients and methods: MBC-6 is a non-randomized, multicenter, open-label, single-arm phase II study in patients with HER2-negative ABC (ClinicalTrials.gov: NCT01891227). All patients were pretreated with anthracyclines and/or taxans and had measurable disease according to RECIST 1.1. Patients received 1000 mg/m2 capecitabine twice daily on days 1 to 14 in combination with 80 mg/m2 bendamustine on day 1 and 8 of a 3-week cycle for a maximum of 6 cycles. Afterwards capecitabine was continued as monotherapy. The primary endpoint was overall response rate (ORR). Secondary endpoints were progression-free survival (PFS), clinical benefit rate (CBR), safety and quality of life.
Results: From September 2013 to May 2015, 40 patients were recruited in eight Austrian centers. Median age was 60 years (range 29-77). Twenty-five percent of patients had triple-negative disease (TNBC) and 93% showed visceral involvement. Sixty-five percent had received prior chemotherapy in the (neo)adjuvant setting and 63% for ABC (43% one line, 15% two lines, 5% three lines). All patients with ER-positive disease had received prior endocrine therapy.At data cut-off on 06/08/16 overall 39 of 40 patients had discontinued treatment with a median PFS of 7.0 months (95% CI 4.6-9.5), 7.4 months in ER-positive and 4.0 months in triple negative disease (TNBC), respectively. Twelve patients (30%) experienced at least one drug related non-hematological AE ≥ grade 3 during combination treatment and further 6 patients (15%) during capecitabine maintenance. Three grade 4 hematological AEs (neutropenia) were observed. One patient died as a result of restrictive cardiomyopathy, where a relationship to capecitabine cannot be excluded, but seems unlikely.
Conclusion: The combination of capecitabine and bendamustine shows promising efficacy and a moderate toxicity profile. Further evaluation of this drug combination is warranted.Background: Capecitabine is a well-established treatment option in HER2-negative advanced breast cancer (ABC) patients. Bendamustine is a generally well tolerated cytotoxic drug. Since bendamustine has already shown anticancer activity in ABC we evaluated the efficacy and tolerability of bendamustine in combination with capecitabine in pretreated patients with ABC. Here we present the final PFS results of this phase II trial.
Patients and methods: MBC-6 is a non-randomized, multicenter, open-label, single-arm phase II study in patients with HER2-negative ABC (ClinicalTrials.gov: NCT01891227). All patients were pretreated with anthracyclines and/or taxans and had measurable disease according to RECIST 1.1. Patients received 1000 mg/m2 capecitabine twice daily on days 1 to 14 in combination with 80 mg/m2 bendamustine on day 1 and 8 of a 3-week cycle for a maximum of 6 cycles. Afterwards capecitabine was continued as monotherapy. The primary endpoint was overall response rate (ORR). Secondary endpoints were progression-free survival (PFS), clinical benefit rate (CBR), safety and quality of life.
Results: From September 2013 to May 2015, 40 patients were recruited in eight Austrian centers. Median age was 60 years (range 29-77). Twenty-five percent of patients had triple-negative disease (TNBC) and 93% showed visceral involvement. Sixty-five percent had received prior chemotherapy in the (neo)adjuvant setting and 63% for ABC (43% one line, 15% two lines, 5% three lines). All patients with ER-positive disease had received prior endocrine therapy.At data cut-off on 06/08/16 overall 39 of 40 patients had discontinued treatment with a median PFS of 7.0 months (95% CI 4.6-9.5), 7.4 months in ER-positive and 4.0 months in triple negative disease (TNBC), respectively. Twelve patients (30%) experienced at least one drug related non-hematological AE ≥ grade 3 during combination treatment and further 6 patients (15%) during capecitabine maintenance. Three grade 4 hematological AEs (neutropenia) were observed. One patient died as a result of restrictive cardiomyopathy, where a relationship to capecitabine cannot be excluded, but seems unlikely.
Conclusion: The combination of capecitabine and bendamustine shows promising efficacy and a moderate toxicity profile. Further evaluation of this drug combination is warranted.
Citation Format: Rinnerthaler G, Gampenrieder SP, Voskova D, Petzer A, Hubalek M, Petru E, Hartmann B, Andel J, Balic M, Melchardt T, Ulmer H, Mlineritsch B, Greil R. Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Final PFS results of a phase II trial (AGMT MBC-6) [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-15-13.
Collapse
Affiliation(s)
- G Rinnerthaler
- Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Cancer Cluster Salzburg, Paracelsus Medical University Salzburg, Salzburg, Austria; Kepler University Linz, Linz, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Innsbruck Medical University, Innsbruck, Austria; Medical University Graz, Graz, Austria; General Hospital Feldkirch, Feldkirch, Austria; County Hospital Steyr, Steyr, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - SP Gampenrieder
- Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Cancer Cluster Salzburg, Paracelsus Medical University Salzburg, Salzburg, Austria; Kepler University Linz, Linz, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Innsbruck Medical University, Innsbruck, Austria; Medical University Graz, Graz, Austria; General Hospital Feldkirch, Feldkirch, Austria; County Hospital Steyr, Steyr, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - D Voskova
- Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Cancer Cluster Salzburg, Paracelsus Medical University Salzburg, Salzburg, Austria; Kepler University Linz, Linz, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Innsbruck Medical University, Innsbruck, Austria; Medical University Graz, Graz, Austria; General Hospital Feldkirch, Feldkirch, Austria; County Hospital Steyr, Steyr, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - A Petzer
- Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Cancer Cluster Salzburg, Paracelsus Medical University Salzburg, Salzburg, Austria; Kepler University Linz, Linz, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Innsbruck Medical University, Innsbruck, Austria; Medical University Graz, Graz, Austria; General Hospital Feldkirch, Feldkirch, Austria; County Hospital Steyr, Steyr, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - M Hubalek
- Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Cancer Cluster Salzburg, Paracelsus Medical University Salzburg, Salzburg, Austria; Kepler University Linz, Linz, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Innsbruck Medical University, Innsbruck, Austria; Medical University Graz, Graz, Austria; General Hospital Feldkirch, Feldkirch, Austria; County Hospital Steyr, Steyr, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - E Petru
- Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Cancer Cluster Salzburg, Paracelsus Medical University Salzburg, Salzburg, Austria; Kepler University Linz, Linz, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Innsbruck Medical University, Innsbruck, Austria; Medical University Graz, Graz, Austria; General Hospital Feldkirch, Feldkirch, Austria; County Hospital Steyr, Steyr, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - B Hartmann
- Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Cancer Cluster Salzburg, Paracelsus Medical University Salzburg, Salzburg, Austria; Kepler University Linz, Linz, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Innsbruck Medical University, Innsbruck, Austria; Medical University Graz, Graz, Austria; General Hospital Feldkirch, Feldkirch, Austria; County Hospital Steyr, Steyr, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - J Andel
- Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Cancer Cluster Salzburg, Paracelsus Medical University Salzburg, Salzburg, Austria; Kepler University Linz, Linz, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Innsbruck Medical University, Innsbruck, Austria; Medical University Graz, Graz, Austria; General Hospital Feldkirch, Feldkirch, Austria; County Hospital Steyr, Steyr, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - M Balic
- Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Cancer Cluster Salzburg, Paracelsus Medical University Salzburg, Salzburg, Austria; Kepler University Linz, Linz, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Innsbruck Medical University, Innsbruck, Austria; Medical University Graz, Graz, Austria; General Hospital Feldkirch, Feldkirch, Austria; County Hospital Steyr, Steyr, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - T Melchardt
- Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Cancer Cluster Salzburg, Paracelsus Medical University Salzburg, Salzburg, Austria; Kepler University Linz, Linz, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Innsbruck Medical University, Innsbruck, Austria; Medical University Graz, Graz, Austria; General Hospital Feldkirch, Feldkirch, Austria; County Hospital Steyr, Steyr, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - H Ulmer
- Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Cancer Cluster Salzburg, Paracelsus Medical University Salzburg, Salzburg, Austria; Kepler University Linz, Linz, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Innsbruck Medical University, Innsbruck, Austria; Medical University Graz, Graz, Austria; General Hospital Feldkirch, Feldkirch, Austria; County Hospital Steyr, Steyr, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - B Mlineritsch
- Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Cancer Cluster Salzburg, Paracelsus Medical University Salzburg, Salzburg, Austria; Kepler University Linz, Linz, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Innsbruck Medical University, Innsbruck, Austria; Medical University Graz, Graz, Austria; General Hospital Feldkirch, Feldkirch, Austria; County Hospital Steyr, Steyr, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - R Greil
- Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Cancer Cluster Salzburg, Paracelsus Medical University Salzburg, Salzburg, Austria; Kepler University Linz, Linz, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Innsbruck Medical University, Innsbruck, Austria; Medical University Graz, Graz, Austria; General Hospital Feldkirch, Feldkirch, Austria; County Hospital Steyr, Steyr, Austria; Medical University Innsbruck, Innsbruck, Austria
| |
Collapse
|
7
|
Brunner C, Ramoni A, Brantner C, Marth C, Hubalek M. Deutlich aufgetriebener Uterus, flüssigkeitsgefüllt mit teilweise soliden Anteilen, bei einer 32-jährigen Patientin mit metastasiertem Mammakarzinom unter laufender palliativer Chemotherapie. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1582206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
8
|
Czech T, Egle T, Hubalek M. Radiatio-induziertes Weichteilsarkom der Mamma- ein Fallbericht. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1579587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
9
|
Hubalek M, Sztankay M, Meraner V, Martini C, Sperner-Unterweger B, Weber I, Morscher R, Zschocke J, Egle D, Dünser M, Oberguggenberger A. Abstract P2-09-22: Long-term psychosocial consequences and counsellees' satisfaction after genetic counselling for hereditary breast- and ovarian cancer - A patient reported outcome study. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p2-09-22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Genetic counselling and testing (GCT) for hereditary breast and ovarian cancer (BOC) has become a standard option in BOC care in Europe allowing for prognostic information on the individual risk for disease onset/ relapse as well as on treatment options comprising prophylactic surgery or surveillance programs. However, data on the psychosocial long-term consequences is limited, especially in high-risk counsellees opting against genetic testing. We aimed at investigating the long-term psychosocial consequences of GCT for hereditary BOC in all counsellees irrespective of their decision after counselling.
Patients and Methods: Counsellees for BOC with and without a previous disease who had undergone genetic counselling at Innsbruck Medical University between 2011 and 2014 were asked to participate in a cross-sectional Patient Reported Outcome (PRO) assessment (incl. Multidimensional Impact of Cancer Risk Assessment, Genetic counseling satisfaction scale, Satisfaction with Decision Scale, Breast Cancer Heredity Knowledge Scale, Hospital Anxiety and Depression Scale/ HADS, Short Form 12 Health Survey, Cancer Worry Scale/ CWS) targeting on psychological distress, cancer worry, patient knowledge and patient satisfaction with genetic counselling and decisions by means of an anonymous mail survey. Subsequent decisions for vs. against genetic testing and if eligible, for surveillance vs. prophylactic surgery were also assessed. A reference sample of BC survivors was recruited at the outpatient unit.
Results: An overall sample of 137 counselees was included in the analysis (67.9% decided to undergo genetic testing for a HCPS, 22.6% decided not to be tested, 9.5% were still uncertain about their decision). 22.6% of counsellees experienced clinically relevant levels of anxiety and 9.8% scored above the cut-off for clinically relevant depression according to the HADS. Mean CWS score was 11 (SD 3.6, 3-24). Counsellees did not differ from breast cancer survivors regarding anxiety and depression according to the HADS (depression: p<0.5). Mean patient satisfaction with decisions amounted to 25.4 (SD 5.78, min. 4 to max. 30); a mean satisfaction with counselling of 25 (5.4) was observed. Less overall satisfaction with genetic counselling (β=0.445, t=5.552, p=0.000) and lower certainty about decision for/ against genetic testing after counselling (β=-0.169, t=-2.105, p=0.037) were highly predictive for lower long-term patient satisfaction with decisions.
Conclusion: Our results indicate that genetic counselling for BOC has no overall deleterious psychosocial consequences in long-term. Levels of depression and anxiety were comparable to those of the general population, while distress levels did not differ from those of breast cancer survivors without a hereditary BOC predisposition. The overall satisfaction with counselling as well as the certainty with decisions on testing and related medical interventions are highly predictive for the long-term satisfaction with decisions. Hence, genetic counselling should focus on supporting counsellees in forming clear decisions and include identifying counsellees with increased cared needs in this regard by means of PRO assessment in follow-up.
Citation Format: Hubalek M, Sztankay M, Meraner V, Martini C, Sperner-Unterweger B, Weber I, Morscher R, Zschocke J, Egle D, Dünser M, Oberguggenberger A. Long-term psychosocial consequences and counsellees' satisfaction after genetic counselling for hereditary breast- and ovarian cancer - A patient reported outcome study. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-09-22.
Collapse
Affiliation(s)
- M Hubalek
- Innsbruck Medical University, Innsbruck, Austria; Division of Human Genetics, Innsbruck Medical University, Innsbruck, Austria
| | - M Sztankay
- Innsbruck Medical University, Innsbruck, Austria; Division of Human Genetics, Innsbruck Medical University, Innsbruck, Austria
| | - V Meraner
- Innsbruck Medical University, Innsbruck, Austria; Division of Human Genetics, Innsbruck Medical University, Innsbruck, Austria
| | - C Martini
- Innsbruck Medical University, Innsbruck, Austria; Division of Human Genetics, Innsbruck Medical University, Innsbruck, Austria
| | - B Sperner-Unterweger
- Innsbruck Medical University, Innsbruck, Austria; Division of Human Genetics, Innsbruck Medical University, Innsbruck, Austria
| | - I Weber
- Innsbruck Medical University, Innsbruck, Austria; Division of Human Genetics, Innsbruck Medical University, Innsbruck, Austria
| | - R Morscher
- Innsbruck Medical University, Innsbruck, Austria; Division of Human Genetics, Innsbruck Medical University, Innsbruck, Austria
| | - J Zschocke
- Innsbruck Medical University, Innsbruck, Austria; Division of Human Genetics, Innsbruck Medical University, Innsbruck, Austria
| | - D Egle
- Innsbruck Medical University, Innsbruck, Austria; Division of Human Genetics, Innsbruck Medical University, Innsbruck, Austria
| | - M Dünser
- Innsbruck Medical University, Innsbruck, Austria; Division of Human Genetics, Innsbruck Medical University, Innsbruck, Austria
| | - A Oberguggenberger
- Innsbruck Medical University, Innsbruck, Austria; Division of Human Genetics, Innsbruck Medical University, Innsbruck, Austria
| |
Collapse
|
10
|
Hubalek M, Sztankay M, Oberguggenberger A, Meraner V, Egle D, Mangweth-Matzek B, Beer B, Huber N, Sperner-Unterweger B. Abstract P1-11-02: Psychological morbidity in breast cancer survivors: Prevalence rates and determinants. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p1-11-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The number of breast cancer survivors (BCS) is steadily increasing due to improved treatment options, early detection and younger age at diagnosis. Thus, it is increasingly important to determine and better understand the psychological outcome following a cancer diagnosis and treatment in long-term. This might contribute to meeting the long-term health care demands of cancer survivors. We aimed at investigating levels and determinants of anxiety and depression (AD) in BCS.
Patients and Methods: We included BCS with a non-metastatic disease in the stage of after-care. AD was determined as part of a cross-sectional, comprehensive patient reported outcome (PRO) assessment (incl. Functional Assessment of Cancer Therapy-G/+B/+ES, Eating Disorder Examination-Questionnaire, Sexual Activity Questionnaire and Body Image Scale) using the Hospital Anxiety and Depression Scale (HADS). Prevalence rates of AD and sample characteristics are presented descriptively using percentages, means and standard deviations. Predictors of anxiety and depression are identified by means of regression analysis.
Results: A final sample of 743 breast cancer survivors who were on average 2.9 years post diagnosis (range: 0.1-11.3 years) participated in the study. Mean patient age was 56.4a (SD 11.5a), 2/3 of patients were postmenopausal. 22.5% of patients reported clinically relevant levels of anxiety and 11.2% of depression. Older age (β=0.012, t=2.53, p<0.05), higher endocrine symptoms (β=-0.037, t=-8.89, p<0.01) and reduced functional well-being (β=-0.034, t=-7.73, p<0.01) were predictive for anxiety and depression in the regression model. The model explained 39.3% of the variance of anxiety and depression.
Conclusion: A distinct proportion of BCS report clinically relevant, long-term psychological morbidity. Especially older BCS, experiencing higher levels of endocrine symptoms and reduced functional well-being, seem to be at risk for psychological morbidity. A routine PRO-screening for psychological morbidity including the assessment of associated risk factors in this patient population might contribute to the identification of those women in need for psychological/ psychiatric treatment and in conjunction, improve cancer care.
Citation Format: Hubalek M, Sztankay M, Oberguggenberger A, Meraner V, Egle D, Mangweth-Matzek B, Beer B, Huber N, Sperner-Unterweger B. Psychological morbidity in breast cancer survivors: Prevalence rates and determinants. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-11-02.
Collapse
Affiliation(s)
- M Hubalek
- Innsbruck Medical University, Innsbruck, Austria; Institute of Legal Medicine and Core Facility Metabolomics, Innsbruck Medical University, Innsbruck, Austria
| | - M Sztankay
- Innsbruck Medical University, Innsbruck, Austria; Institute of Legal Medicine and Core Facility Metabolomics, Innsbruck Medical University, Innsbruck, Austria
| | - A Oberguggenberger
- Innsbruck Medical University, Innsbruck, Austria; Institute of Legal Medicine and Core Facility Metabolomics, Innsbruck Medical University, Innsbruck, Austria
| | - V Meraner
- Innsbruck Medical University, Innsbruck, Austria; Institute of Legal Medicine and Core Facility Metabolomics, Innsbruck Medical University, Innsbruck, Austria
| | - D Egle
- Innsbruck Medical University, Innsbruck, Austria; Institute of Legal Medicine and Core Facility Metabolomics, Innsbruck Medical University, Innsbruck, Austria
| | - B Mangweth-Matzek
- Innsbruck Medical University, Innsbruck, Austria; Institute of Legal Medicine and Core Facility Metabolomics, Innsbruck Medical University, Innsbruck, Austria
| | - B Beer
- Innsbruck Medical University, Innsbruck, Austria; Institute of Legal Medicine and Core Facility Metabolomics, Innsbruck Medical University, Innsbruck, Austria
| | - N Huber
- Innsbruck Medical University, Innsbruck, Austria; Institute of Legal Medicine and Core Facility Metabolomics, Innsbruck Medical University, Innsbruck, Austria
| | - B Sperner-Unterweger
- Innsbruck Medical University, Innsbruck, Austria; Institute of Legal Medicine and Core Facility Metabolomics, Innsbruck Medical University, Innsbruck, Austria
| |
Collapse
|
11
|
Egle D, Hubalek M, Hager C, Poyßl C, Lang A, Jäger T, Volgger B, Abdel-Azim S, Tiechl J, Angerer J, Marth C. Abstract P4-14-11: Efficacy and cardiac safety in neoadjuvant treatment of Her2 positive breast cancer with concomitant nonpegylated liposomal doxorubicin, docetaxel and dual blockade with trastuzumab and pertuzumab: A retrospective analysis. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p4-14-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Approval to pertuzumab as part of a complete treatment regimen for patients with early stage breast cancer (EBC) before surgery (neoadjuvant setting) was granted by the FDA in September 2013. Since then, the relevance of neoadjuvant treatment in Her2 overexpressing breast cancer has increased considerably. This for instance has been emphasized by the results of the Neosphere Study, in which dual blockade of Her2 was combined with docetaxel as chemotherapy backbone and resulted in favorable pCR rates.
But it is likely, that anthracyclines could play an important role in enhancing the effectiveness of the above mentioned treatment. However, there is only little data about the cardiac safety of this combination. The use of liposomal doxorubicin might be a valuable alternative with low cardiotoxicity, as it has been shown in comparable publications without the use of pertuzumab. Therefore we report pCR-rate and cardiac safety of a single arm, retrospective, multicenter analysis of neoadjuvant treatment for Her2 positive EBC with liposomal doxorubicin, docetaxel, trastuzumab and pertuzumab.
Methods: In this study 42 women with Her2 positive EBC were investigated in 4 oncological departments in Austria. 41 patients were treated with liposomal doxorubicin (50 mg/m2), docetaxel (75 mg/m2) concurrent with trastuzumab and pertuzumab in standard dosage for 6 cycles as neoadjuvant therapy. One patient refused to receive a chemotherapy but agreed to be treated with combined antibody therapy alone. All patients were free of cardiovascular disease and had a left ventricular ejection fraction (LVEF) of ≥ 50%. Cardiac function was measured by LVEF and was examined at regular intervals (cycles 0-3, cycle 6, FU). Clinical response was evaluated by diagnostic breast imaging after cycles 3 and 6. All patients underwent surgery after neoadjuvant chemotherapy. The absence of any residual invasive cancer in the breast and axilla was defined as pathological complete response (pCR). Median follow up was 1.3 years.
Results: Median age of the patients was 49 years. After 6 cycles of treatment the pCR rate was 76.2%. In this cohort a negative estrogen-and/or progesteron receptor was predictive for pCR (p<0.001). These patients achieved pCR in 95.2%. The antibody only treatment in one case also resulted in a pCR. No patient progressed during treatment. Only one of the patients (2,4%) suffered symptomatic heart failure after surgery. The patient initially presented with an LVEF of 16%.
Conclusions: In this multicenter analysis we observed a considerably high rate of pCR in HER2-positive EBC treated with liposomal doxorubicin, docetaxel, trastuzumab and pertuzumab. Especially the group of hormone receptor negative patients showed a remarkable response rate. The addition of liposomal doxorubicin entails a very favorable cardiotoxicity profile. This regimen is a safe treatment option in patients with HER-2 positive breast cancer.
Citation Format: Egle D, Hubalek M, Hager C, Poyßl C, Lang A, Jäger T, Volgger B, Abdel-Azim S, Tiechl J, Angerer J, Marth C. Efficacy and cardiac safety in neoadjuvant treatment of Her2 positive breast cancer with concomitant nonpegylated liposomal doxorubicin, docetaxel and dual blockade with trastuzumab and pertuzumab: A retrospective analysis. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-14-11.
Collapse
Affiliation(s)
- D Egle
- University Hospital Innsbruck, Innsbruck, Tirol, Austria; KH Dornbirn, Dornbirn, Vorarlberg, Austria; LKH Feldkirch, Feldkirch, Vorarlberg, Austria; KH Lienz, Lienz, Tirol, Austria
| | - M Hubalek
- University Hospital Innsbruck, Innsbruck, Tirol, Austria; KH Dornbirn, Dornbirn, Vorarlberg, Austria; LKH Feldkirch, Feldkirch, Vorarlberg, Austria; KH Lienz, Lienz, Tirol, Austria
| | - C Hager
- University Hospital Innsbruck, Innsbruck, Tirol, Austria; KH Dornbirn, Dornbirn, Vorarlberg, Austria; LKH Feldkirch, Feldkirch, Vorarlberg, Austria; KH Lienz, Lienz, Tirol, Austria
| | - C Poyßl
- University Hospital Innsbruck, Innsbruck, Tirol, Austria; KH Dornbirn, Dornbirn, Vorarlberg, Austria; LKH Feldkirch, Feldkirch, Vorarlberg, Austria; KH Lienz, Lienz, Tirol, Austria
| | - A Lang
- University Hospital Innsbruck, Innsbruck, Tirol, Austria; KH Dornbirn, Dornbirn, Vorarlberg, Austria; LKH Feldkirch, Feldkirch, Vorarlberg, Austria; KH Lienz, Lienz, Tirol, Austria
| | - T Jäger
- University Hospital Innsbruck, Innsbruck, Tirol, Austria; KH Dornbirn, Dornbirn, Vorarlberg, Austria; LKH Feldkirch, Feldkirch, Vorarlberg, Austria; KH Lienz, Lienz, Tirol, Austria
| | - B Volgger
- University Hospital Innsbruck, Innsbruck, Tirol, Austria; KH Dornbirn, Dornbirn, Vorarlberg, Austria; LKH Feldkirch, Feldkirch, Vorarlberg, Austria; KH Lienz, Lienz, Tirol, Austria
| | - S Abdel-Azim
- University Hospital Innsbruck, Innsbruck, Tirol, Austria; KH Dornbirn, Dornbirn, Vorarlberg, Austria; LKH Feldkirch, Feldkirch, Vorarlberg, Austria; KH Lienz, Lienz, Tirol, Austria
| | - J Tiechl
- University Hospital Innsbruck, Innsbruck, Tirol, Austria; KH Dornbirn, Dornbirn, Vorarlberg, Austria; LKH Feldkirch, Feldkirch, Vorarlberg, Austria; KH Lienz, Lienz, Tirol, Austria
| | - J Angerer
- University Hospital Innsbruck, Innsbruck, Tirol, Austria; KH Dornbirn, Dornbirn, Vorarlberg, Austria; LKH Feldkirch, Feldkirch, Vorarlberg, Austria; KH Lienz, Lienz, Tirol, Austria
| | - C Marth
- University Hospital Innsbruck, Innsbruck, Tirol, Austria; KH Dornbirn, Dornbirn, Vorarlberg, Austria; LKH Feldkirch, Feldkirch, Vorarlberg, Austria; KH Lienz, Lienz, Tirol, Austria
| |
Collapse
|
12
|
Rinnerthaler G, Gampenrieder SP, Fridrik M, Petzer A, Hubalek M, Petru E, Jäger T, Andel J, Balic M, Ulmer H, Mlineritsch B, Greil R. Abstract P1-13-10: Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Stage 1 results of a phase II trial (AGMT MBC-6). Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p1-13-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Although there is no single accepted standard of care after failure of anthracycline and taxane therapy in HER2-negative metastatic breast cancer, capecitabine is a well-established treatment option. Bendamustine is a hybrid cytotoxic drug because of its structural similarity to alkylating agents and purine and it is generally well tolerated. Since bendamustine has already shown anticancer activity in breast cancer we evaluated the efficacy and tolerability of bendamustine in combination with capecitabine in 40 patients with advanced breast cancer after anthracycline and/or taxane pretreatment.
Patients and methods: MBC-6 is a non-randomized, multicenter, open-label, single-arm phase II study in patients with HER2-negative advanced breast cancer (ClinicalTrials.gov identifier: NCT01891227). All patients were pretreated with anthracyclines and/or taxans in the (neo-)adjuvant and/or metastatic setting and measurable disease according to RECIST 1.1. had to be present at baseline. Following a two-stage Green-Dahlberg design, 20 subjects were accrued and treated within stage 1 of the study. The trial was planned to enroll further 20 patients if there were at least four subjects (20%) with a complete (CR) or partial response (PR). Eligible patients received 1000 mg/m2 capecitabine twice daily on days 1 to 14 in combination with 80 mg/m2 bendamustine on day 1 and 8 of a 3-week cycle. After a maximum of eight cycles capecitabine was continued as single drug therapy until disease progression or unacceptable toxicity. The primary endpoint was overall response rate (ORR). Secondary endpoints were progression free survival (PFS), clinical benefit rate (CBR), safety profile and quality of life. Here we report the efficacy and safety analysis of stage 1 patients.
Results: From September 2013 to May 2015, 40 patients were recruited in eight Austrian centers. Median age of the stage 1 cohort was 59 years (range 29-77), 80% and 20% of patients had an ECOG performance score of 0 and 1, respectively. Thirty-three percent had triple-negative disease, 85% had had (neo-)adjuvant treatment and 65% patients were pretreated with at least one chemotherapy line for metastatic disease (15% one line, 50% two lines, 40% three lines). In stage 1, ORR was 50% with 9 confirmed PR and 1 confirmed CR, and ORR was comparable between hormone receptor-positive and triple-negative disease (54% vs. 43%). CBR was 55%. At data cut-off on 05/28/15 overall 15 of 20 patients had discontinued treatment: 10 patients (50%) due to progressive disease, 3 (15%) because of adverse events (AEs) and 2 patients on their own decision (10%). Five patients (25%) experienced at least one drug related non-hematological AE ≥ grade 3: 2 diarrhea, 2 fatigue, 3 respiratory or viral infections, 1 dyspnea, 1 thromboembolic event (each grade 3). One grade 4 hematological AE (neutropenia) was observed. One patient died as a result of restrictive cardiomyopathy, where a relationship to capecitabine cannot be excluded, but seems unlikely.
Conclusion: The combination of capecitabine and bendamustine has a moderate toxicity profile and the response data of the stage 1 are promising. Final study results are awaited in the first half of 2016.
Citation Format: Rinnerthaler G, Gampenrieder SP, Fridrik M, Petzer A, Hubalek M, Petru E, Jäger T, Andel J, Balic M, Ulmer H, Mlineritsch B, Greil R. Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Stage 1 results of a phase II trial (AGMT MBC-6). [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-13-10.
Collapse
Affiliation(s)
- G Rinnerthaler
- Salzburg Cancer Research Institute With Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria; General Hospital Linz, Linz, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Innsbruck Medical University, Innsbruck, Austria; Medical University Graz, Innsbruck, Austria; General Hospital Feldkirch, Feldkirch, Austria; County Hospital Steyr, Steyr, Austria; Division of Oncology, Medical University Graz, Graz, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - SP Gampenrieder
- Salzburg Cancer Research Institute With Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria; General Hospital Linz, Linz, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Innsbruck Medical University, Innsbruck, Austria; Medical University Graz, Innsbruck, Austria; General Hospital Feldkirch, Feldkirch, Austria; County Hospital Steyr, Steyr, Austria; Division of Oncology, Medical University Graz, Graz, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - M Fridrik
- Salzburg Cancer Research Institute With Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria; General Hospital Linz, Linz, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Innsbruck Medical University, Innsbruck, Austria; Medical University Graz, Innsbruck, Austria; General Hospital Feldkirch, Feldkirch, Austria; County Hospital Steyr, Steyr, Austria; Division of Oncology, Medical University Graz, Graz, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - A Petzer
- Salzburg Cancer Research Institute With Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria; General Hospital Linz, Linz, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Innsbruck Medical University, Innsbruck, Austria; Medical University Graz, Innsbruck, Austria; General Hospital Feldkirch, Feldkirch, Austria; County Hospital Steyr, Steyr, Austria; Division of Oncology, Medical University Graz, Graz, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - M Hubalek
- Salzburg Cancer Research Institute With Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria; General Hospital Linz, Linz, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Innsbruck Medical University, Innsbruck, Austria; Medical University Graz, Innsbruck, Austria; General Hospital Feldkirch, Feldkirch, Austria; County Hospital Steyr, Steyr, Austria; Division of Oncology, Medical University Graz, Graz, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - E Petru
- Salzburg Cancer Research Institute With Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria; General Hospital Linz, Linz, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Innsbruck Medical University, Innsbruck, Austria; Medical University Graz, Innsbruck, Austria; General Hospital Feldkirch, Feldkirch, Austria; County Hospital Steyr, Steyr, Austria; Division of Oncology, Medical University Graz, Graz, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - T Jäger
- Salzburg Cancer Research Institute With Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria; General Hospital Linz, Linz, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Innsbruck Medical University, Innsbruck, Austria; Medical University Graz, Innsbruck, Austria; General Hospital Feldkirch, Feldkirch, Austria; County Hospital Steyr, Steyr, Austria; Division of Oncology, Medical University Graz, Graz, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - J Andel
- Salzburg Cancer Research Institute With Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria; General Hospital Linz, Linz, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Innsbruck Medical University, Innsbruck, Austria; Medical University Graz, Innsbruck, Austria; General Hospital Feldkirch, Feldkirch, Austria; County Hospital Steyr, Steyr, Austria; Division of Oncology, Medical University Graz, Graz, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - M Balic
- Salzburg Cancer Research Institute With Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria; General Hospital Linz, Linz, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Innsbruck Medical University, Innsbruck, Austria; Medical University Graz, Innsbruck, Austria; General Hospital Feldkirch, Feldkirch, Austria; County Hospital Steyr, Steyr, Austria; Division of Oncology, Medical University Graz, Graz, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - H Ulmer
- Salzburg Cancer Research Institute With Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria; General Hospital Linz, Linz, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Innsbruck Medical University, Innsbruck, Austria; Medical University Graz, Innsbruck, Austria; General Hospital Feldkirch, Feldkirch, Austria; County Hospital Steyr, Steyr, Austria; Division of Oncology, Medical University Graz, Graz, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - B Mlineritsch
- Salzburg Cancer Research Institute With Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria; General Hospital Linz, Linz, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Innsbruck Medical University, Innsbruck, Austria; Medical University Graz, Innsbruck, Austria; General Hospital Feldkirch, Feldkirch, Austria; County Hospital Steyr, Steyr, Austria; Division of Oncology, Medical University Graz, Graz, Austria; Medical University Innsbruck, Innsbruck, Austria
| | - R Greil
- Salzburg Cancer Research Institute With Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria; General Hospital Linz, Linz, Austria; Barmherzige Schwestern Hospital Linz, Linz, Austria; Innsbruck Medical University, Innsbruck, Austria; Medical University Graz, Innsbruck, Austria; General Hospital Feldkirch, Feldkirch, Austria; County Hospital Steyr, Steyr, Austria; Division of Oncology, Medical University Graz, Graz, Austria; Medical University Innsbruck, Innsbruck, Austria
| |
Collapse
|
13
|
Jahn B, Rochau U, Kurzthaler C, Hubalek M, Miksad R, Sroczynski G, Paulden M, Kluibenschädl M, Krahn M, Siebert U. Cost effectiveness of personalized treatment in women with early breast cancer: the application of OncotypeDX and Adjuvant! Online to guide adjuvant chemotherapy in Austria. Springerplus 2015; 4:752. [PMID: 26693110 PMCID: PMC4666888 DOI: 10.1186/s40064-015-1440-6] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/12/2015] [Accepted: 10/14/2015] [Indexed: 11/10/2022]
Abstract
A Breast Cancer Outcomes model was developed at the ONCOTYROL research center to evaluate personalized test-treatment strategies in Austria. The goal was to evaluate the cost-effectiveness of a new 21-gene assay (ODX) when used in conjunction with the Adjuvant! Online (AO) decision aid to support personalized decisions about use of adjuvant chemotherapy in early-stage breast cancer patients in Austria. We applied a validated discrete-event-simulation model to a hypothetical cohort of 50 years old women over a lifetime horizon. The test-treatment strategies of interest were defined using three-letter acronyms. The first (second, third) letter indicates whether patients with a low (intermediate, high) risk according to AO were tested using ODX (Y yes, N no). The main outcomes were life-years gained, quality-adjusted life-years (QALYs), costs and cost effectiveness. Robustness of the results was tested in sensitivity analyses. Results were compared to a Canadian analysis conducted by the Toronto Health Economics and Technology Assessment Collaborative (THETA). Five of eight strategies were dominated (i.e., more costly and less effective: NNY, NYN, YNN, YNY, YYN). The base-case analysis shows that YYY (ODX provided to all patients) is the most effective strategy and is cost effective with an incremental cost-effectiveness ratio of 15,700 EUR per QALY gained. These results are sensitive to changes in the probabilities of distant recurrence, age and costs of chemotherapy. The results of the base-case analysis were comparable to the THETA results. Based on our analyses, using ODX in addition to AO is effective and cost effective in all women in Austria. The development of future genetic tests may require alternative or additional test-treatment strategies to be evaluated.
Collapse
Affiliation(s)
- B Jahn
- Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Eduard Wallnoefer Center 1, A-6060 Hall i.T, Austria ; Division of Public Health Decision Modelling, Health Technology Assessment and Health Economics, ONCOTYROL - Center for Personalized Cancer Medicine, Innsbruck, Austria
| | - U Rochau
- Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Eduard Wallnoefer Center 1, A-6060 Hall i.T, Austria ; Division of Public Health Decision Modelling, Health Technology Assessment and Health Economics, ONCOTYROL - Center for Personalized Cancer Medicine, Innsbruck, Austria
| | - C Kurzthaler
- Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Eduard Wallnoefer Center 1, A-6060 Hall i.T, Austria ; Division of Public Health Decision Modelling, Health Technology Assessment and Health Economics, ONCOTYROL - Center for Personalized Cancer Medicine, Innsbruck, Austria
| | - M Hubalek
- Department of Obstetrics and Gynaecology, Medical University Innsbruck, Innsbruck, Austria
| | - R Miksad
- Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA USA
| | - G Sroczynski
- Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Eduard Wallnoefer Center 1, A-6060 Hall i.T, Austria ; Division of Public Health Decision Modelling, Health Technology Assessment and Health Economics, ONCOTYROL - Center for Personalized Cancer Medicine, Innsbruck, Austria
| | - M Paulden
- Toronto Health Economics and Technology Assessment (THETA) Collaborative, University of Toronto, Toronto, ON Canada ; Department of Emergency Medicine, University of Alberta, Edmonton, AB Canada
| | - M Kluibenschädl
- Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Eduard Wallnoefer Center 1, A-6060 Hall i.T, Austria ; Division of Public Health Decision Modelling, Health Technology Assessment and Health Economics, ONCOTYROL - Center for Personalized Cancer Medicine, Innsbruck, Austria
| | - M Krahn
- Toronto Health Economics and Technology Assessment (THETA) Collaborative, University of Toronto, Toronto, ON Canada
| | - U Siebert
- Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Eduard Wallnoefer Center 1, A-6060 Hall i.T, Austria ; Division of Public Health Decision Modelling, Health Technology Assessment and Health Economics, ONCOTYROL - Center for Personalized Cancer Medicine, Innsbruck, Austria ; Center for Health Decision Science, Department of Health Policy and Management, T.H.Chan Harvard School of Public Health, Boston, MA USA ; Institute for Technology Assessment and Department of Radiology, Harvard Medical School, Massachusetts General Hospital, Boston, MA USA
| |
Collapse
|
14
|
Daniaux M, Auer T, De Zordo T, Junker D, Santner W, Hubalek M, Jaschke W, Aigner F. Strain Elastography of Breast and Prostata Cancer: Similarities and Differences. ROFO-FORTSCHR RONTG 2015; 188:253-8. [PMID: 26529265 DOI: 10.1055/s-0041-106540] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
UNLABELLED Typically both breast and prostate cancer present as tissue with decreased elasticity. Palpation is the oldest technique of tumor detection in both organs and is based on this principle. Thus an operator can grade a palpable mass as suspicious for cancer. Strain elastography as modern ultrasound technique allows the visualization of tissue elasticity in a color coded elastogram and can be understood as technical finger. The following article shows similarities and differences of ultrasound strain elastography in the diagnosis of breast and prostate cancer. KEY POINTS • In prostata cancer elastography, in breast cancer B-mode is the primary sonographic search modality. • The diagnostic value of the search modalities change with increasing age.• A cut-off value for a strain ratio is hard to obtain in the elastography of the prostata, because there is no stabile reference tissue in the prostata.
Collapse
Affiliation(s)
- M Daniaux
- Radiology, Medical University Innsbruck, Austria
| | - T Auer
- Radiology, Medical University Innsbruck, Austria
| | - T De Zordo
- Radiology, Medical University Innsbruck, Austria
| | - D Junker
- Radiology, Medical University Innsbruck, Austria
| | - W Santner
- Radiology, Hirslanden, Clinic Aarau, Switzerland
| | - M Hubalek
- Gynecology, Medical University Innsbruck, Austria
| | - W Jaschke
- Radiology, Medical University Innsbruck, Austria
| | - F Aigner
- Radiology, Medical University Innsbruck, Austria
| |
Collapse
|
15
|
Hüfner K, Oberguggenberger A, Kohl C, Geisler S, Gamper E, Meraner V, Egeter J, Hubalek M, Beer B, Fuchs D, Sperner-Unterweger B. Levels in neurotransmitter precursor amino acids correlate with mental health in patients with breast cancer. Psychoneuroendocrinology 2015; 60:28-38. [PMID: 26112459 DOI: 10.1016/j.psyneuen.2015.06.001] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/12/2015] [Revised: 06/01/2015] [Accepted: 06/01/2015] [Indexed: 12/19/2022]
Abstract
Breast cancer is the most common cancer among females. Approximately 30% of cancer patients develop depression or depressive adaptation disorder within 5 years post diagnosis. Low grade inflammation and subsequent changes in neurotransmitter levels could be the pathophysiological link. In the current study we investigated the association of neurotransmitter precursor amino acids with a diagnosis of depression or state anxiety in 154 subjects suffering from breast cancer (BCA(+)), depression (DPR(+)), both or neither. Sociodemographic parameters, severity of depressive symptoms, and state anxiety (ANX) were recorded. Neopterin, kynurenine/tryptophan and phenylalanine/tyrosine were analysed by HPLC or ELISA. Significantly higher serum neopterin values were found in DPR(+) patients (p = 0.034) and in ANX(+) subjects (p = 0.008), as a marker of Th1-related inflammation. The phenylalanine/tyrosine ratio (index of the catecholamine pathway) was associated with the factors "breast cancer" and "depression" and their interaction (all p < 0.001); it was highest in the DPR(+)BCA(+) group. The kynurenine/tryptophan ratio (index of the serotonin pathway) was significantly associated with the factors "breast cancer" and "state anxiety" and their interaction (p < 0.001, p = 0.026, p = 0.02, respectively); it was highest in the ANX(+)BCA(+) group. In BCA(+) patients kynurenine/tryptophan ratios correlated with severity of state anxiety (r = 0.226, p = 0.048, uncorrected) and phenylalanine/tyrosine ratios with severity of depressive symptoms (r = 0.376, p < 0.05, corrected). In conclusion, levels of neurotransmitter precursor amino acids correlate with mental health, an effect which was much more pronounced in BCA(+) patients than in BCA(-) subjects. Aside from identifying underlying pathophysiological mechanisms, these results could be the basis for future treatment studies: in BCA(+) patients with depression the use of serotonin-noradrenaline reuptake inhibitors might be recommended while in those with predominant anxiety selective serotonin reuptake inhibitors might be the treatment of choice.
Collapse
Affiliation(s)
- K Hüfner
- Department of Psychiatry and Psychotherapy, Medical University of Innsbruck, Anichstr. 35, 6020 Innsbruck, Austria.
| | - A Oberguggenberger
- Department of Psychiatry and Psychotherapy, Medical University of Innsbruck, Anichstr. 35, 6020 Innsbruck, Austria
| | - C Kohl
- Department of Psychiatry and Psychotherapy, Medical University of Innsbruck, Anichstr. 35, 6020 Innsbruck, Austria
| | - S Geisler
- Division of Biological Chemistry, Biocenter, Medical University of Innsbruck, Innsbruck, Austria
| | - E Gamper
- Department of Psychiatry and Psychotherapy, Medical University of Innsbruck, Anichstr. 35, 6020 Innsbruck, Austria
| | - V Meraner
- Department of Psychiatry and Psychotherapy, Medical University of Innsbruck, Anichstr. 35, 6020 Innsbruck, Austria
| | - J Egeter
- Department of Psychiatry and Psychotherapy, Medical University of Innsbruck, Anichstr. 35, 6020 Innsbruck, Austria
| | - M Hubalek
- Department of Gynecology and Obstetrics, Medical University of Innsbruck, Innsbruck, Austria
| | - B Beer
- Institute of Legal Medicine, Medical University of Innsbruck, Innsbruck, Austria
| | - D Fuchs
- Division of Biological Chemistry, Biocenter, Medical University of Innsbruck, Innsbruck, Austria
| | - B Sperner-Unterweger
- Department of Psychiatry and Psychotherapy, Medical University of Innsbruck, Anichstr. 35, 6020 Innsbruck, Austria
| |
Collapse
|
16
|
Schaffenrath H, Engleder N, Faltner B, Salzer J, Wegscheider H, Hubalek M, Egle D. Einfluss von subkutanem Trastuzumab auf den Faktor Zeit im klinischen Alltag. Geburtshilfe Frauenheilkd 2015. [DOI: 10.1055/s-0035-1555082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
17
|
Kocher F, Dobner S, Föger B, Fiegl M, Fridrik M, Hubalek M, Lang A, Pall G, Petzer A, Wöll E, Hilbe W. Cardiovascular complications of cancer treatment: update CACOCA trial. Pneumologie 2015. [DOI: 10.1055/s-0035-1551918] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
18
|
Dale I, Roscher A, Fiegel H, Turco EGD, Hubalek M, Himmel I, Prader S, Troi C, Carvalho AL, Vieira RDC. P274 New circulating lipid markers related to breast cancer. Breast 2015. [DOI: 10.1016/s0960-9776(15)70306-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
19
|
Steger G, Greil R, Hubalek M, Fridrik M, Singer C, Bartsch R, Balic M, Dubsky P, Egle D, Gampenrieder S, Pfeiler G, Mayr D, Czech T, Rinnerthaler G, Petzer A, Sevelda P, Lang A, Frantal S, Rudas M, Gnant M. Docetaxel + Trastuzumab +/- Non-Pegylated Liposomal Doxorubicin +/- Bevacizumab in the Neoadjuvant Treatment of Early, Her2-Positive Breast Cancer: First Results of Abcsg-32. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu327.10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
20
|
Steger GG, Greil R, Lang A, Rudas M, Fitzal F, Mlineritsch B, Hartmann BL, Bartsch R, Melbinger E, Hubalek M, Stoeger H, Dubsky P, Ressler S, Petzer AL, Singer CF, Muss C, Jakesz R, Gampenrieder SP, Zielinski CC, Fesl C, Gnant M. Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24). Ann Oncol 2013; 25:366-71. [PMID: 24347519 DOI: 10.1093/annonc/mdt508] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND This randomized phase III trial compared pathologic complete response (pCR) rates of early breast cancer (EBC) following neoadjuvant epirubicin-docetaxel (ED)±capecitabine (C), and evaluated the addition of trastuzumab in HER2-positive tumors. PATIENTS AND METHODS Patients with invasive breast cancer (except T4d) were randomly assigned to receive six 3-weekly cycles of ED (both 75 mg/m2)±C (1000 mg/m2, twice daily, days 1-14). Patients with HER2-positive disease were further randomized to receive trastuzumab (8 mg/kg, then 6 mg/kg every 3 weeks) or not. Primary end point: pCR rate at the time of surgery. RESULTS Five hundred thirty-six patients were randomized to ED (n=266) or EDC (n=270); 93 patients were further randomized to trastuzumab (n=44) or not (n=49). pCR rate was significantly increased with EDC (23.0% versus 15.4% ED, P=0.027), and nonsignificantly further increased with trastuzumab (38.6% EDC versus 26.5% ED, P=0.212). Rates of axillary node involvement at surgery and breast conservation were improved with EDC versus ED, but not significantly; the addition of trastuzumab had no further impact. Hormone receptor status, tumor size, grade, and C (all P≤0.035) were independent prognostic factors for pCR. Trastuzumab added to ED±C significantly increased the number of serious adverse events (35 versus 18; P=0.020), mainly due to infusion-related reactions. CONCLUSION These findings show that the integration of C into a neoadjuvant taxane-/anthracycline-based regimen is a feasible, safe, and effective treatment option, with incorporation of trastuzumab in HER2-positive disease. CLINICAL TRIAL NUMBER NCT00309556, www.clinicaltrials.gov.
Collapse
Affiliation(s)
- G G Steger
- Department of Internal Medicine I, Division of Oncology and Comprehensive Cancer Center, Medical University of Vienna, Vienna
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Brunner C, Müller-Holzner E, Marth C, Lang A, Jäger T, Stöger H, Suppan C, Hubalek M. Eine Multicenter Studie über die kardiotoxische Sicherheit und Effektivität der neoadjuvanten Therapie mit liposomalem Doxorubicin (Myocet®), Docetaxel (Taxotere®) und Trastuzumab (Herceptin®) bei Patieninnen mit HER2-positivem Mammakarzinom. Geburtshilfe Frauenheilkd 2013. [DOI: 10.1055/s-0033-1336795] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
22
|
Net N, Wimmer A, Schoeller T, Bauer T, Daniaux M, Marth C, Hubalek M. Patientinnenzufriedenheit und onkologische Sicherheit bei Skin-sparing mastectomy versus Areola-sparing mastectomy mit Simultanrekonstruktion mittels Eigengewebe. Geburtshilfe Frauenheilkd 2013. [DOI: 10.1055/s-0033-1336794] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
23
|
Strobl EM, Oberguggenberger A, Meraner V, Beer B, Giesinger J, Kemmler G, Oberacher H, Sperner-Unterweger B, Holzner B, Marth C, Hubalek M. Hat der CYP 2D6 Genotyp Einfluss auf Nebenwirkungen und Adherence? Prämenopausale Brustkrebs-Patientinnen unter Tamoxifen-Therapie. Geburtshilfe Frauenheilkd 2013. [DOI: 10.1055/s-0033-1336791] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
24
|
Berger A, Oberguggenberger A, Sztankay M, Meraner V, Beer B, Oberacher H, Giesinger J, Kemmler G, Egle D, Gamper EM, Sperner-Unterweger B, Holzner B, Marth C, Hubalek M. Wird die Toxizität einer adjuvanten Therapie mit Aromataseinhibitoren unterschätzt? Zusätzliche Informationen durch Patientinnen Feedback Fragebögen. Geburtshilfe Frauenheilkd 2013. [DOI: 10.1055/s-0033-1336792] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
25
|
Ritter M, Egle D, Oberguggenberger A, Nehoda R, Sztankay M, Meraner V, Giesinger J, Sperner-Unterweger B, Holzner B, Beer B, Oberacher H, Marth C, Hubalek M. Profitieren adipöse Frauen weniger von der adjuvanten endokrinen Therapie mit Aromataseinhibitoren? Der Zusammenhang von BMI und den Plasmaspiegeln von Aromataseinibitoren, dargestellt in einer umfangreichen Studie. Geburtshilfe Frauenheilkd 2013. [DOI: 10.1055/s-0033-1336793] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
26
|
Drevinek M, Dresler J, Klimentova J, Pisa L, Hubalek M. Evaluation of sample preparation methods for MALDI-TOF MS identification of highly dangerous bacteria. Lett Appl Microbiol 2012; 55:40-6. [PMID: 22512320 DOI: 10.1111/j.1472-765x.2012.03255.x] [Citation(s) in RCA: 51] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
AIMS To propose a universal workflow of sample preparation method for the identification of highly pathogenic bacteria by MALDI-TOF MS. METHODS AND RESULTS Fifteen bacterial species, including highly virulent Gram-positive (Bacillus anthracis and Clostridium botulinum) and Gram-negative bacteria (Brucella melitensis, Burkholderia mallei, Francisella tularensis, Shigella dysenteriae, Vibrio cholerae, Yersinia pestis and Legionella pneumophila), were employed in the comparative study of four sample preparation methods compatible with MALDI-TOF MS. The yield of bacterial proteins was determined by spectrophotometry, and the quality of the mass spectra, recorded in linear mode in the range of 2000-20,000 Da, was evaluated with respect to the information content (number of signals) and quality (S/N ratio). CONCLUSIONS Based on the values of protein concentration and spectral quality, the method using combination of ethanol treatment followed by extraction with formic acid and acetonitrile was the most efficient sample preparation method for the identification of highly pathogenic bacteria using MALDI-TOF MS. SIGNIFICANCE AND IMPACT OF THE STUDY The method using ethanol/formic acid generally shows the highest extraction efficacy and the spectral quality with no detrimental effect caused by storage. Thus, this can be considered as a universal sample preparation method for the identification of highly virulent micro-organisms by MALDI-TOF mass spectrometry.
Collapse
Affiliation(s)
- M Drevinek
- National Institute for Nuclear, Chemical and Biological Protection, Pribram-Kamenna, Czech Republic.
| | | | | | | | | |
Collapse
|
27
|
Knapp I, Nehoda R, Hubalek M, Marth C. Die junge Mammakarzinompatientin: schlechte Prognose aufgrund des Alters? Geburtshilfe Frauenheilkd 2012. [DOI: 10.1055/s-0032-1309212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
28
|
Finkenstedt A, Widschwendter A, Brasse-Lagnel C, Theurl I, Hubalek M, Dieplinger H, Tselepis C, Ward D, Vogel W, Zoller H. Hepcidin is correlated to soluble hemojuvelin but not to increased GDF15 during pregnancy. Blood Cells Mol Dis 2012; 48:233-7. [DOI: 10.1016/j.bcmd.2012.02.001] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2011] [Revised: 10/20/2011] [Accepted: 01/30/2012] [Indexed: 10/28/2022]
|
29
|
Hubalek M, Bartsch R, Gnant M, Kapp KS, Lang A, Lax S, Lukas P, Neunteufel W, Pristauz G, Reitsamer R, Sandbichler P, Schrenk P, Singer C, Tamussino K, Tschmelitsch J, Zeimet AG, Marth C. Axillary Dissection in the Case of Positive Sentinel Lymph Nodes: Results of the Innsbruck Consensus Conference. Geburtshilfe Frauenheilkd 2012; 72:293-298. [PMID: 25284834 DOI: 10.1055/s-0031-1298441] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Abstract
The prognosis of breast cancer is most heavily influenced by the status of the axillary nodes. Until a few years ago, this knowledge was gained through radical axillary lymph node clearance. In the meantime, sentinel lymph node clearance has become an established part of the surgical treatment of breast cancer. With the development of this procedure, the morbidity caused by axillary dissection has been reduced significantly. Although comprehensive prospective, randomised data regarding the safe use of the sentinel concept are only now available, the focus currently, however, is on the question of whether in the case of positive sentinel lymph nodes, an axillary dissection can be done away with altogether without having any negative impact on the risk of loco-regional recurrence or on progression-free survival and overall survival. The results of the American ACOSOG-Z001 study have changed the fundamental perspective of this. In this study on the advantages of axillary dissection following the confirmation of tumour tissue in the sentinel lymph nodes, there were no statistically significant advantages from axillary dissection for women with a favourable overall risk profile who had received radiotherapy and systemic therapy. If this concept takes hold, the surgical treatment of node-positive breast cancer, at least in the axilla, would be reduced to a minimum, and the focus of treatment would in future lie more on the systemic treatment of this condition. As part of an interdisciplinary consensus meeting, a standardised approach for Austria with regard to this question was decided upon.
Collapse
Affiliation(s)
- M Hubalek
- Department of Women's Health, Clin. Dept. of Gynaecology and Obstetrics, Innsbruck, Austria
| | - R Bartsch
- University Department of Internal Medicine I, Breast Health Centre MUW/AKH, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria
| | - M Gnant
- University Department of Surgery, Breast Health Centre MUW/AKH, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria
| | - K S Kapp
- University Department of Radiotherapy/Radio-Oncology, Graz, Austria
| | - A Lang
- Feldkirch State Hospital, Dept. of Internal Medicine, Haematology and Medical Oncology, Feldkirch, Austria
| | - S Lax
- Graz West State Hospital, Institute of Pathology, Graz, Austria
| | - P Lukas
- University Department of Radiotherapy/Radio-Oncology, Innsbruck, Austria
| | - W Neunteufel
- Dornbirn Hospital, Department of Gynaecology and Obstetrics, Dornbirn, Austria
| | - G Pristauz
- University Department of Gynaecology and Obstetrics, Clinical Department of Gynaecology, Graz, Austria
| | - R Reitsamer
- St. Johanns-Spital/State Women's Hospital, University Department of Specialist Gynaecology, Salzburg, Austria
| | - P Sandbichler
- St.Vinzenz Hospital, Department of Surgery, Zams, Austria
| | - P Schrenk
- Linz City Hospital, Dept. of Surgery II, Breast Competence Centre, Linz, Austria
| | - C Singer
- Clinical Department of General Gynaecology and Gynaecological Oncology, Medical University of Vienna, Vienna, Austria
| | - K Tamussino
- University Department of Gynaecology and Obstetrics, Clinical Department of Gynaecology, Graz, Austria
| | - J Tschmelitsch
- Hospital of the Merciful Brothers, Surgical Department, St. Veit/Glan, Austria
| | - A G Zeimet
- Department of Women's Health, Clin. Dept. of Gynaecology and Obstetrics, Innsbruck, Austria
| | - C Marth
- Department of Women's Health, Clin. Dept. of Gynaecology and Obstetrics, Innsbruck, Austria
| |
Collapse
|
30
|
Vavra C, Singer C, Staudigl C, Hubalek M, Unterrieder K, Jäger C, Sevelda P. G-CSF Prophylaxe bei Hochrisikopatientinnen mit soliden Tumoren in der klinischen Praxis: IMPACT SOLID Studie. Geburtshilfe Frauenheilkd 2012. [DOI: 10.1055/s-0032-1309206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
31
|
Lang A, Muendlein A, Hartmann BL, Drexel H, Decker T, Fricke H, Hofmann W, Mueller-Holzner E, Marth C, Hubalek M. Association of a common genetic variant of the IGF1 gene with clinical outcome in patients with HER2-positive breast cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.27_suppl.193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
193 Background: Insulin-like growth factor 1 (IGF1) stimulates mitosis and inhibits apoptosis. Circulating IGF1 levels may be linked with an increased risk of colorectal and breast cancer. Further, IGF1 single nucleotide polymorphisms (SNPs), especially variant rs2946834, recently have been associated with a poor clinical outcome in patients with colorectal cancer. However, the influence of IGF1 SNPs on the prognosis of patients with breast cancer is unknown. Therefore, we aimed at investigating the influence of IGF1 tagging polymorphisms associated with IGF1 levels on event-free survival in patients with HER2-positive breast cancer. Methods: The present study included 161 consecutive white patients with HER2-positive breast cancer treated between 2000 and 2010 at the Department of Gynecology and Obstetrics, Medical University of Innsbruck, Austria. Event-free survival was calculated as the time from cancer diagnosis to either relapse or death from any cause. Genomic DNA was extracted from archived formalin-fixed paraffin embedded tumor tissue samples; five IGF1 tagging polymorphisms (rs2946834, rs6220, rs1520220, rs5742694, and rs5742678) were genotyped by SNaPshot assays. Results: Mean follow up period was 4.3 (± 2.5) years. Kaplan-Meier analysis showed a poorer clinical outcome for carriers of the rare allele of SNP rs2946834 (log-rank test, p = 0.029). Concordantly, in univariate Cox regression analyses the rare allele of SNP rs2946834 was significantly associated with a decreased event-free survival (HR = 2.87 [1.07 –7.70]; p = 0.036). Multivariate analysis adjusted for age and tumor stage confirmed this result (HR = 2.86 [1.06 –7.71]; p = 0.038). Thus, our results are in concordance with a recent report that the same SNP is associated with poorer clinical outcome in colorectal cancer patients. Other investigated genetic variants of the IGF1 gene were not significantly associated with event-free survival (all p-values > 0.05). Conclusions: For the first time, our study investigates the influence of IGF1 tagging polymorphisms on the clinical outcome of HER2-positive breast cancer patients suggesting SNP rs2946834 as a predictor for reduced event-free survival.
Collapse
Affiliation(s)
- A. Lang
- Academic Teaching Hospital Feldkirch, Feldkirch, Austria; Vorarlberg Institute for Vascular Investigation and Treatment, Feldkirch, Austria; Onkologie Ravensburg, Muenster, Germany; Klinikum Konstanz, Konstanz, Germany; GATC Biotech AG, Konstanz, Germany; Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria
| | - A. Muendlein
- Academic Teaching Hospital Feldkirch, Feldkirch, Austria; Vorarlberg Institute for Vascular Investigation and Treatment, Feldkirch, Austria; Onkologie Ravensburg, Muenster, Germany; Klinikum Konstanz, Konstanz, Germany; GATC Biotech AG, Konstanz, Germany; Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria
| | - B. L. Hartmann
- Academic Teaching Hospital Feldkirch, Feldkirch, Austria; Vorarlberg Institute for Vascular Investigation and Treatment, Feldkirch, Austria; Onkologie Ravensburg, Muenster, Germany; Klinikum Konstanz, Konstanz, Germany; GATC Biotech AG, Konstanz, Germany; Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria
| | - H. Drexel
- Academic Teaching Hospital Feldkirch, Feldkirch, Austria; Vorarlberg Institute for Vascular Investigation and Treatment, Feldkirch, Austria; Onkologie Ravensburg, Muenster, Germany; Klinikum Konstanz, Konstanz, Germany; GATC Biotech AG, Konstanz, Germany; Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria
| | - T. Decker
- Academic Teaching Hospital Feldkirch, Feldkirch, Austria; Vorarlberg Institute for Vascular Investigation and Treatment, Feldkirch, Austria; Onkologie Ravensburg, Muenster, Germany; Klinikum Konstanz, Konstanz, Germany; GATC Biotech AG, Konstanz, Germany; Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria
| | - H. Fricke
- Academic Teaching Hospital Feldkirch, Feldkirch, Austria; Vorarlberg Institute for Vascular Investigation and Treatment, Feldkirch, Austria; Onkologie Ravensburg, Muenster, Germany; Klinikum Konstanz, Konstanz, Germany; GATC Biotech AG, Konstanz, Germany; Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria
| | - W. Hofmann
- Academic Teaching Hospital Feldkirch, Feldkirch, Austria; Vorarlberg Institute for Vascular Investigation and Treatment, Feldkirch, Austria; Onkologie Ravensburg, Muenster, Germany; Klinikum Konstanz, Konstanz, Germany; GATC Biotech AG, Konstanz, Germany; Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria
| | - E. Mueller-Holzner
- Academic Teaching Hospital Feldkirch, Feldkirch, Austria; Vorarlberg Institute for Vascular Investigation and Treatment, Feldkirch, Austria; Onkologie Ravensburg, Muenster, Germany; Klinikum Konstanz, Konstanz, Germany; GATC Biotech AG, Konstanz, Germany; Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria
| | - C. Marth
- Academic Teaching Hospital Feldkirch, Feldkirch, Austria; Vorarlberg Institute for Vascular Investigation and Treatment, Feldkirch, Austria; Onkologie Ravensburg, Muenster, Germany; Klinikum Konstanz, Konstanz, Germany; GATC Biotech AG, Konstanz, Germany; Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria
| | - M. Hubalek
- Academic Teaching Hospital Feldkirch, Feldkirch, Austria; Vorarlberg Institute for Vascular Investigation and Treatment, Feldkirch, Austria; Onkologie Ravensburg, Muenster, Germany; Klinikum Konstanz, Konstanz, Germany; GATC Biotech AG, Konstanz, Germany; Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria
| |
Collapse
|
32
|
Reimer D, Kiefel H, Hubalek M, Erdel M, Concin N, Hofstetter G, Mueller-Holzner E, Altevogt P, Marth C, Zeimet AG. Epidermal growth factor-mediated signaling in ovarian cancer and the role of miR-34a and 6p22 gene amplification-based E2F3a control. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e15535] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
33
|
Egle D, Oberguggenberger A, Achleitner R, Sztankay M, Meraner V, Giesinger J, Sperner-Unterweger B, Holzner B, Beer B, Oberacher H, Marth C, Hubalek M. Do obese women benefit less from adjuvant endocrine therapy with aromatase inhibitors? Preliminary analysis on the association of BMI and aromatase inhibitor plasma levels. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e11118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
34
|
Hubalek M, Oberguggenberger A, Meraner V, Beer B, Giesinger J, Oberacher H, Sperner-Unterweger B, Marth C. Abstract P4-02-04: Impact of CYP2D6 Genotype and Side-Effects on Adherence Rates to Tamoxifen in Premenopausal Breast Cancer Patients. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p4-02-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Only few studies have investigated the issue of breast cancer patients’ adherence to tamoxifen therapy and factors influencing adherence behavior. Especially in the context of different CYP2D6 genotypes adherence to tamoxifen has not been extensively studied yet. Variations in the CYP2D6 genotype, as well as patients taking inhibitors of CYP2D6 (e.g. antidepressants) contribute to different side effects and adherence rates to adjuvant tamoxifen.
Materials and Methods: 106 premenopausal breast cancer patients who met inclusion criteria were consecutively included in the study at the outpatient unit of the Department of Gynecology, Innsbruck Medical University. Within their routine after care appointment patients completed a comprehensive PRO assessment including the FACT-B/ES, the HADS and a self-report questionnaire on adherence behavior (SMAQ). The multi-method approach comprised the Simplified Medication Adherence Questionnaire, a semi-structured interview, physicians’ ratings and blood levels for tamoxifen metabolites. Additionally, the CYP2D6 genotype was determined in all patients participating in this part of the study.
Results: 19% patients were poor metabolizer (PM), 51% intermediate metabolizer (IM), 29% extensive metabolizer (EM) and 7% ultra-rapid metabolizer (UM). Significant group differences with regard to tamoxifen and endoxifen serum concentrations were found between the metabolization groups (p=0.044). UMs had the lowest tamoxifen and highest endoxifen concentrations. Only 3.2% of the patients analyzed had no measurable tamoxifen concentrations in their serum. All non-compilant patients were from the extensive metabolizer group. However, during follow-up 25% (2/6) of patients with UM genotype, 13% (4/30) with EM genotype, 1% (1/50) with IM genotype and 0% (0/19) with the PM genotype discontinued their tamoxifen therapy due to therapy related side effects. In addition anti-depressants were more frequently prescribed in the extensive metabolizer group leading to lower levels of the active metabolite endoxifen. Conclusion: A trend towards higher hot flashes was observed in the EM and UM group. We did not find significant differences in QOL between
CYP2D6 metabolizing groups. Trend level significance was found for global QOL (on a descriptive level) physical well-being and emotional well-being. Non-adherence to tamoxifen therapy is more frequent in patients with CYP2D6 EM and UM genotype. These preliminary data may explain part of the current controversy over CYP2D6 genotype predicting response to tamoxifen and suggest that patients most likely to benefit from tamoxifen are paradoxically most likely to stop their tamoxifen therapy prematurely.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P4-02-04.
Collapse
Affiliation(s)
- M Hubalek
- Medical University Innsbruck, Austria
| | | | - V Meraner
- Medical University Innsbruck, Austria
| | - B Beer
- Medical University Innsbruck, Austria
| | | | | | | | - C. Marth
- Medical University Innsbruck, Austria
| |
Collapse
|
35
|
Schubert B, Beer B, Oberguggenberger A, Meraner V, Holzner B, Hubalek M, Oberacher H. Abstract P5-11-09: A Validated Analytical Method for Monitoring the Plasma Levels of Tamoxifen, Anastrozole and Letrozole in Patients Undergoing Endocrine Therapy. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p5-11-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Clinical data have repeatedly shown that tamoxifen as well as anastrazole and letrozole significantly increase the overall survival among breast cancer patients. However, in several cases the use of these drugs is limited by side effects, whose appearance are described to impair the adherence of a patient to endocrine treatment. Frequently, adherence is rated based on patient self-reports. One competent approach to obtain impartial information about patient adherence and its clinical relevance is based on the determination of plasma drug concentrations. The individual steady state plasma level represents an objective measure that may serve as an important comparator to check the patient-reported adherence status in clinical studies. In addition, it may also reveal useful information for the treating physician regarding concentration dependent side effects or therapeutic failure. We have developed and validated a liquid chromatography-tandem mass spectrometry (LC/MS/MS) method for the simultaneous analysis of tamoxifen, anastrazole and letrozole in human plasma. The method was applied in the PRO-BETh study to monitor 320 breast cancer patients undergoing endocrine therapy.
Material and methods: Blood plasma samples were collected from 320 patients undergoing endocrine breast cancer therapy and stored at -20° C. To prepare a sample for LC/MS/MS analysis, 1 ml plasma was treated with a solid phase extraction procedure using a cation mixed-mode polymeric sorbent phase (Strata-X-C cartridges, Phenomenex, CA). Chromatographic separation was accomplished on a reversed-phase column (200 mm x 0.5 mm, Eurosphere-C18, 5 μm, Knauer, Berlin) by using a gradient of acetone in an aqueous hexafluorobutyric acid solution. Mass spectrometric detection was performed on a quadrupole-quadrupole-linear ion trap instrument (Q Trap 3200, Applied Biosystems, Foster City, CA). Results: We have developed a fully validated method for the simultaneous quantitative analysis of tamoxifen, anastrozole and letrozole in human plasma. Validation was accomplished for a concentration range of 25-500 ng/ml for tamoxifen, 10-200 ng/ml for endoxifen, 5-200 ng/ml for anastrozol and 10-300 ng/ml for letrozole. The applicability of the method was demonstrated in the context of the PRO-BETh study, by analyzing plasma samples of 320 patients undergoing endocrine breast cancer therapy. The observed plasma levels showed a high inter-patient variability with measured values between 26-307 ng/ml (mean 125 ng/ml) regarding tamoxifen, 17-301 ng/ml (mean 107 ng/ml) regarding letrozole and 6-102 ng/ml (mean 37 ng/ml) regarding anastrozole. Eight samples did not contain a quantifiable amount of drug, indicating longer abstinence of the corresponding patients regarding endocrine therapy. Conclusions: The developed method represents a reliable and convenient tool for the quantitative analysis of tamoxifen, anastrozol and letrozole in human plasma. The method is dedicated to drug monitoring which is an important part of adherence rating. As exemplified in the context of the PRO-BETh study, the measured steady state plasma levels represent objective measures that serve as important comparators to check the patient-reported adherence status.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P5-11-09.
Collapse
Affiliation(s)
- B Schubert
- Innsbruck Medical University, Innbruck, Austria; Innsbruck Medical University, Innsbruck, Austria
| | - B Beer
- Innsbruck Medical University, Innbruck, Austria; Innsbruck Medical University, Innsbruck, Austria
| | - A Oberguggenberger
- Innsbruck Medical University, Innbruck, Austria; Innsbruck Medical University, Innsbruck, Austria
| | - V Meraner
- Innsbruck Medical University, Innbruck, Austria; Innsbruck Medical University, Innsbruck, Austria
| | - B Holzner
- Innsbruck Medical University, Innbruck, Austria; Innsbruck Medical University, Innsbruck, Austria
| | - M Hubalek
- Innsbruck Medical University, Innbruck, Austria; Innsbruck Medical University, Innsbruck, Austria
| | - H. Oberacher
- Innsbruck Medical University, Innbruck, Austria; Innsbruck Medical University, Innsbruck, Austria
| |
Collapse
|
36
|
Hubalek M, Oberguggenberger A, Beer B, Meraner V, Oberacher H, Sperner-Unterweger B, Kemmler G, Holzner B, Marth C. Abstract P5-11-10: Gonadotropins Plasma Levels Are Significantly Influenced by Body Mass Index in Postmenopausal Breast Cancer Patients Undergoing Endocrine Therapy with Aromatase Inhibitors: Is This a Surrogate Marker for Serum Estrogen Bioactivity? Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p5-11-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Estrogens play a crucial role in breast carcinogenesis and progression. The third-generation aromatase inhibitors (AIs) have therefore become the first choice endocrine drugs for post-menopausal women with breast cancer, since they present greater efficacy when compared with tamoxifen. However, mode of action, side effects and tolerability are distinct compared to tamoxifen. In this study, we evaluated clinical side-effects, levels of gonadotropin, prolactin, progesterone and estradiol in postmenopausal women undergoing endocrine treatment with aromatase inhibitors.
Materials and Methods: 128 postmenopausal patients undergoing endocrine therapy with aromatase inhibitors were included in the study. They completed the assessment at their regular 3-month check up. For the assessment of side-effects and symptom burden we used the FACT-B/+ES and the HADS. Blood samples were collected within the routine blood collection and measurement of follicle stimulation hormone (FSH), luteinizing hormone (LH), progesterone, estradiol and prolactin plasma levels were performed by Immunoassay. Data were analyzed using Spearman rank correlation.
Results: We found a significant negative correlation of LH and FSH with body mass index (BMI) of postmenopausal breast cancer patients (LH r=- 0.281, p=0.014; FSH r=-0.250, p=0.029) receiving aromatase inhibitors. Analyses revealed a significant positive correlation for LH and FSH levels with subjectively experienced weight gain (LH r=0.499, p=0.008; FSH r=0.550, p=0.003), dyspareunia and vaginal dryness. Moreover, patients with a BMI ≥25 had significantly more gynaecological symptoms (dyspareunia p=0.008 and vaginal dryness p=0.026) than patients witha lower BMI. Progesterone was significantly associated with subjective weight gain (r=0.248, p=0.014). Prolactin significantly correlated with loss of sex drive (r=0.256, p=0.050), mood swings (r=0.239, p=0.050) and irritability (r=0.244, p=0.046).
Conclusion: Our results reveal distinct endocrine changes among postmenopausal breast cancer patients undergoing endocrine treatment with AIs. These results confirm the central role of estrogens in the evolution of adverse events to aromatase inhibitors. The main observation in this study, however, was the correlation of BMI and levels of hormone influenced by estrogenic activity. LH and FSH which are under control of various estrogen metabolites, were significantly associated with the BMI and might therefore serve as surrogate marker of estrogenic activity in serum of breast cancer patients. Direct measurement of estradiol (E2) showed no correlation with BMI indicating the influence of various other estrogen metabolites on the secretion of gonadotropins. Analysis of serum estrogen receptor bioactivity in these patients is currently underway.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P5-11-10.
Collapse
Affiliation(s)
- M Hubalek
- Medical University Innsbruck, Austria
| | | | - B Beer
- Medical University Innsbruck, Austria
| | - V Meraner
- Medical University Innsbruck, Austria
| | | | | | - G Kemmler
- Medical University Innsbruck, Austria
| | - B Holzner
- Medical University Innsbruck, Austria
| | - C. Marth
- Medical University Innsbruck, Austria
| |
Collapse
|
37
|
Beer B, Erb R, Plattner S, Hubalek M, Oberguggenberger A, Meraner V, Oberacher H. Abstract P4-02-17: Polymerase Chain Reaction-Liquid Chromatography-Mass Spectrometry — A Convenient and Cost-Effective Strategy for CYP2D6 Genotyping. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p4-02-17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Genetic polymorphisms in the drug metabolizing enzyme Cyotchrome P450 2D6 (CYP2D6) gene can significantly influence a person's ability to mediate CYP2D6 dependent metabolism. For example, a notable influence of the CYP2D6 genotype has been described regarding the conversion of tamoxifen to its pharmacologically active metabolites. Thus, the genetic determination of the CYP2D6 metabolizer status has the potential to represent a valuable therapeutic supplement in breast cancer therapy. However, the clinical relevance of the CYP2D6 genotype regarding the treatment of breast cancer with tamoxifen still remains to be elucidated. Due to the high number of relevant polymorphisms to be screened, pharmacogenetic CYP2D6 testing is considered to be time-consuming and laborious and is therefore limited to a few clinical studies only. To enable a more widespread use, we present polymerase chain reaction (PCR) - ion-pair reversed-phase high-performance liquid chromatography — electrospray ionization time of flight mass spectrometry (ICEMS) as fast, convenient and cost-effective strategy for CYP2D6 genotyping.
Material and Methods: After DNA extraction from saliva swabs, the CYP2D6 gene was amplified by a long range PCR. Subsequently, polymorphism-specific short amplicons were generated in a multiplexed PCR. The amplicons were directly analysed by ICEMS. The information necessary to determine the allelic state of a PCR-amplified polymorphic locus were obtained from the measured molecular masses. Gene duplications or deletions were analysed by a long range PCR protocol and subsequent agarose gel detection.
Results: The developed CYP2D6 genotyping approach enables the reliable determination of the most frequent CYP2D6 alleles in Europe (*1, *2, *3, *4, *6, *7, *8, *9, *10, *11, *12, *17, *41) including whole gene duplications and deletions (*5). The assay involves the following steps: (1) collecting biological material in form of non-invasive saliva swabs; (2) DNA extraction; (3) long range PCR for a specific CYP2D6 amplification; (3) multiplexed PCR for the generation of polymorphism-specific short amplicons; (4) direct analysis of the reaction mixture with ICEMS; (4) determination of the allelic state with the measured molecular masses; (5) analysis of gene duplications or deletions by a long range PCR protocol and subsequent agarose gel detection. Genotyping of a single sample costs about 5-10 USD and can be accomplished within 2-3 days. Parallelization increases the sample throughput and reduces costs. For proof of principle, we have applied the developed method in the context of the PRO-BETh study to determine the CYP2D6 status of 106 breast cancer patients treated with tamoxifen. According to the classification of Gaedik A. et al [1], 19% of the typed breast cancer patients turned out to be “Poor Metabolizers", 51% were “Intermediate Metabolizers", 29% were “Extensive Metabolizers” and 7% turned out to be “Ultrarapid Metabolizers”.
Conclusion: PCR-ICEMS represents a cost-effective and convenient tool for pharmacogenetic testing, which enables the determination of the CYP2D6 status using DNA obtained from a non-invasive saliva swab as template.
[1] Gaedigk A. et al, J. Clin Pharmacol Ther. 2007 Jun;81(6):817-20.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P4-02-17.
Collapse
Affiliation(s)
- B Beer
- Innsbruck Medical University, Innsbruck, Austria
| | - R Erb
- Innsbruck Medical University, Innsbruck, Austria
| | - S Plattner
- Innsbruck Medical University, Innsbruck, Austria
| | - M Hubalek
- Innsbruck Medical University, Innsbruck, Austria
| | | | - V Meraner
- Innsbruck Medical University, Innsbruck, Austria
| | - H. Oberacher
- Innsbruck Medical University, Innsbruck, Austria
| |
Collapse
|
38
|
Beer B, Schubert B, Hubalek M, Meraner V, Oberguggenberger A, Sperner-Unterweger B, Oberacher H. Abstract P5-11-04: Phenotype-Genotype Correlations in Breast Cancer Patients Treated with Tamoxifen. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p5-11-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Personalized medicine strategies are especially relevant for drugs which show a high inter-individual variability regarding their pharmacokinetic and -dynamic properties. Considerable inter-patient variations have been described regarding the plasma concentrations of tamoxifen and its metabolites. Due to the observation that tamoxifen metabolites can show a high pharmacological activity, tamoxifen metabolism has received considerable attention. The metabolism of tamoxifen is complex resulting in a huge number of different products. Important metabolic transformation reactions include demethylation catalyzed by Cytochrome P450 3A4 and hydroxylation mainly catalyzed by Cytochrome P450 2D6 (CYP2D6). The impact of the CYP2D6 activity, which can be predicted from genetic information, on plasma levels and the related pharmacological effects has controversially been discussed. To get a better understanding of the inter-individual differences of the plasma levels of tamoxifen and some of its metabolites we have used liquid chromatography-tandem mass spectrometry (LC/MS/MS) to screen the plasma samples of 106 breast cancer patients. This method enabled the quantification of tamoxifen as well as a relative quantification of demethyltamoxifen and hydroxylated tamoxifen metabolites. To study the impact of enzyme activity on plasma levels, CYP2D6 genotypes were determined as well.
Material and methods: For metabolic profiling 1 ml plasma was treated with a solid phase extraction procedure. Chromatographic separation was accomplished on a reversed-phase column. Analytes were detected by mass spectrometry. For genotyping, the CYP2D6 gene was amplified by a long range PCR followed by a multiplexed PCR to generate specific short amplicons. The amplicons were directly analysed by LC/MS. The information necessary to determine the allelic state were obtained from the measured molecular masses.
Results: We determined the CYP2D6 genotype of 106 breast cancer patients treated with tamoxifen. We found 19% “Poor Metabolizers", 51% “Intermediate Metabolizers", 29% “Extensive Metabolizers” and 7% “Ultrarapid Metabolizers”. The observed plasma concentrations of tamoxifen and its metabolites showed a high inter-patient variability For instance, plasma concentrations between 26-307 ng/ml (mean 125 ng/ml) were observed for tamoxifen. We did not find a significant impact of the CYP2D6 status on tamoxifen plasma levels. However, the demethyltamoxifen/tamoxifen as well as the hydroxytamoxifen/tamoxifen ratios appear to be influenced by the CYP2D6 status: the higher the metabolic activity, the higher the hydroxytamoxifen content and the lower the demethyltamoxifen content.
Conclusions: We have developed analytical tools, which allow the determination of the content of tamoxifen and its major metabolites in human plasma and the genotyping of the CYP2D6 gene. Phenotypic and genotypic data of 106 patients were acquired. Correlation of the data revealed that the genotype had no significant impact on tamoxifen plasma levels. Nevertheless, patients with a predicted higher CYP2D6 activity showed lower demethyltamoxifen/tamoxifen ratios as well as higher hydroxytamoxifen/tamoxifen ratios.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P5-11-04.
Collapse
Affiliation(s)
- B Beer
- Innsbruck Medical University, Innsbruck, Austria
| | - B Schubert
- Innsbruck Medical University, Innsbruck, Austria
| | - M Hubalek
- Innsbruck Medical University, Innsbruck, Austria
| | - V Meraner
- Innsbruck Medical University, Innsbruck, Austria
| | | | | | - H. Oberacher
- Innsbruck Medical University, Innsbruck, Austria
| |
Collapse
|
39
|
Hubalek M, Oberguggenberger A, Meraner V, Giesinger J, Kemmler G, Sperner-Unterweger B, Beer B, Oberacher H, Marth C, Holzner B. Abstract PD08-02: The Impact of Patient Reported Outcomes (PRO) on the Evaluation of Therapy Related Side-Effects and the Improvement of Adherence to Endocrine Treatment in Breast Cancer Patients. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-pd08-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Long term treatment regimen with significant side effects may diminish a patient's quality of life (QOL) and consequently undermine adherence. Endocrine treatment for breast cancer causes various side effects, which can lead to early discontinuation of this effective therapy. Current knowledge on patients’ quality of life (QOL) impairments caused by endocrine therapy originates from clinicians’ impressions and expert ratings. This runs the risk of underestimating the effects of endocrine therapy on patients’ quality of life. Patient reported outcome (PRO) may provide higher accuracy and may therefore essentially contribute to medication evaluation and clinical decision making. In this study, we report on the patient reported outcome (PRO) related to endocrine therapy in early breast cancer.
Methods: Pre-and postmenopausal breast cancer outpatients treated with aromatase inhibitors (AIS) or tamoxifen were approached at their routine control appointment with the treating physician. We conducted a comprehensive PRO assessment comprising the following scales: FACT-B/+ES and HADS (high scores indicate high symptoms). In a short, semi-structured interview data on patients’ general medication intake behavior were collected focusing on the intake of complementary and alternative medicine (CAM)
Results: We analyzed PRO data of 240 patients undergoing endocrine treatment. 66.6% received AI therapy, 71.9% were postmenopausal. We found high levels of symptom burden in this study group: 55.9% had moderate to severe bone pain, 47.8% menopausal symptoms and 49.1% loss of sex drive. Postmenopausal women in the AI group had significantly more symptoms on the endocrine subscale (mean 24.25 vs. 16.42, p=0.045), significantly more anxiety (mean 8.8 vs. 5.11, p=0.036) and depression (mean 8.75 vs. 3.86, p=0.011). In the tamoxifen group premenopausal patients scored significantly higher on all scales. Moreover, patients who used complementary substances had a significant lower physical well-being (22.70 vs. 24.39, p=0.007) and more endocrine symptoms (22.63 vs. 16.30, p=0.004).
Conclusion:The results of our study show a significantly higher assessment of physical side-effects and psychosocial burden on part of the patients than implied by clinicians’ reports and expert ratings. PRO data may therefore provide a more accurate measure for symptom burden and contribute to individualized clinical decision making. It is an important tool to detect and effectively treat therapy related side effect to ultimately preserve adherence to endocrine treatment. According to our findings, it appears mandatory to incorporate PRO data in individualized clinical decision making to arrive at a more accurate assessment of symptom burden.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr PD08-02.
Collapse
Affiliation(s)
- M Hubalek
- Medical University Innsbruck, Austria
| | | | - V Meraner
- Medical University Innsbruck, Austria
| | | | - G Kemmler
- Medical University Innsbruck, Austria
| | | | - B Beer
- Medical University Innsbruck, Austria
| | | | - C Marth
- Medical University Innsbruck, Austria
| | | |
Collapse
|
40
|
Reimer D, Hubalek M, Riedle S, Skvortsov S, Erdel M, Müller-Holzner E, Fiegl H, Marth C, Altevogt P, Zeimet AG. Molekulare Grundlage und Funktion der EGF-E2F3a Achse in der Tumorbiologie des Ovarialkarzinoms. Geburtshilfe Frauenheilkd 2010. [DOI: 10.1055/s-0030-1252096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
41
|
Beer B, Schubert B, Oberguggenberger A, Meraner V, Holzner B, Hubalek M, Oberacher H. 37 A validated analytical method for the simultaneous quantification of tamoxifen, endoxifen, anastrozole and letrozole. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)70068-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
42
|
Meraner V, Oberguggenberger A, Giesinger J, Hubalek M, Beer B, Schubert B, Sperner-Unterweger B, Holzner B. 377 Patient-reported outcomes in breast cancer patients undergoing endocrine therapy (PRO-BETh): adherence rates and symptom burden over the disease trajectory. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)70403-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
43
|
Hubalek M. 374 Patient-reported outcomes in breast cancer patients undergoing endocrine therapy (PRO-BETh): impact of CYP2D6 genotype and side-effects on adherence rates. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)70400-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
44
|
Reimer D, Hubalek M, Riedle S, Skvortsov S, Erdel M, Concin N, Fiegl H, Müller-Holzner E, Marth C, Altevogt P, Zeimet AG. Die Bedeutung von E2F3a in der EGFR vermittelten Proliferation im Ovarialkarzinom – Biologische und klinische Relevanz. Geburtshilfe Frauenheilkd 2009. [DOI: 10.1055/s-0029-1239005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
45
|
Reimer D, Hubalek M, Riedle S, Skvortsov S, Erdel M, Mueller-Holzner E, Marth C, Altevogt P, Zeimet AG. Regulation of the EGFR-E2F3a axis by the interferon regulatory factor (IRFs) and by promoter methylation of miR-34a in ovarian cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e16522] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e16522 Background: Although, EGFR targeting has reached “bedside” in various tumor entities, including ovarian cancer, the essential role of E2F3a in EGFR mediated proliferation remained uncovered. Recently, we outlined the clinical relevance of E2F3a in ovarian cancer. Now we were able to elucidate the pathway between EGFR activation and E2F3a induction. Methods: Promoter mapping of E2F family members was assessed using the JASPER software. E2F3a protein was assessed by immunoblot analyses in siRNA based IRF-1, IRF-2 knockdown HOC-7 cells. Cell growth was determined by MTT assays after siRNA based knockdown of E2F3a. Expression of E2F3a regulating miR-34a, miR-210 and miR-20a were assessed by RT-PCR in 130 ovarian cancer patients and methylation status of the E2F3a promoter and of miRNA promoters were estimated using Methyllight. 6p22 amplification status of patients was determined by FISH analyses. Results: Promoter mapping of E2F family members revealed that IRF-1 and IRF-2 are potential intermediate components of the herein described EGFR-E2F3a axis. As evidenced by knock-down of IRF-1, IRF-2 or both, the ratio between the two mutually antagonistic IRF-1 and IRF-2 was found to be substantial for EGF induced E2F3a up-regulation. E2F3a knock-down yielded a complete abolishment of EGF induced cancer cell proliferation. Although, activated EGFR status showed a highly significant correlation with E2F3a expression, a subgroup of patients presented high E2F3a mRNA levels without EGFR activation. Within this subgroup promoter methylation of miRNA-34a, that regulates E2F3a, was revealed to represent an alternative mechanism of E2F3a regulation in ovarian cancer, whereas promoter methylation of E2F3a itself was not relevant in E2F3a control. Unlike in prostate or bladder cancer 6p22 amplification was not found to be relevant for E2F3a up-regulation in ovarian cancer. Conclusions: Our present data point to the substantial role of the ratio between IRF-1 and IRF-2 in EGFR mediated E2F3a induction. Furthermore, in vivo regulation of E2F3a involves methylation and thereby silencing of miR-34a. Targeting of the herein described molecular pathway, downstream EGFR, could represent an appealing therapeutic approach in ovarian cancer. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- D. Reimer
- Innsbruck Medical University, Innsbruck, Austria; German Cancer Research Center, Heidelberg, Germany
| | - M. Hubalek
- Innsbruck Medical University, Innsbruck, Austria; German Cancer Research Center, Heidelberg, Germany
| | - S. Riedle
- Innsbruck Medical University, Innsbruck, Austria; German Cancer Research Center, Heidelberg, Germany
| | - S. Skvortsov
- Innsbruck Medical University, Innsbruck, Austria; German Cancer Research Center, Heidelberg, Germany
| | - M. Erdel
- Innsbruck Medical University, Innsbruck, Austria; German Cancer Research Center, Heidelberg, Germany
| | - E. Mueller-Holzner
- Innsbruck Medical University, Innsbruck, Austria; German Cancer Research Center, Heidelberg, Germany
| | - C. Marth
- Innsbruck Medical University, Innsbruck, Austria; German Cancer Research Center, Heidelberg, Germany
| | - P. Altevogt
- Innsbruck Medical University, Innsbruck, Austria; German Cancer Research Center, Heidelberg, Germany
| | - A. G. Zeimet
- Innsbruck Medical University, Innsbruck, Austria; German Cancer Research Center, Heidelberg, Germany
| |
Collapse
|
46
|
Reimer DU, Hubalek M, Wiedmair A, Porto V, Auer D, Mueller-Holzner E, Marth C, Zeimet AG. Clinical relevance of a novel EGF pathway directly linked to E2F3a in ovarian cancer. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.5588] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
47
|
Reimer D, Wiedemair A, Hubalek M, Auer D, Marth C, Zeimet AG. Unterschiedliche Regulation der Isoformen E2F3a und E2F3b durch EGF im Ovarialkarzinom. Geburtshilfe Frauenheilkd 2008. [DOI: 10.1055/s-2008-1078353] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
48
|
Kölle D, Sergi C, Biskup I, Hubalek M. Erfolgreiche Schwangerschaft nach Chorionkarzinom – Fallbericht und Literaturübersicht. Geburtshilfe Frauenheilkd 2008. [DOI: 10.1055/s-2008-1078302] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
49
|
Hubalek M, Fessler S, Zeimet AG, Brezinka C, Mueller-Holzner E, Marth C. Chemotherapeutische Behandlung eines Dysgerminoms in der Schwangerschaft. Geburtshilfe Frauenheilkd 2007. [DOI: 10.1055/s-2007-983546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
50
|
Shafer WM, Katzif S, Bowers S, Fallon M, Hubalek M, Reed MS, Veprek P, Pohl J. Tailoring an antibacterial peptide of human lysosomal cathepsin G to enhance its broad-spectrum action against antibiotic-resistant bacterial pathogens. Curr Pharm Des 2002; 8:695-702. [PMID: 11945165 DOI: 10.2174/1381612023395376] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Neutrophils contain several cationic antimicrobial proteins or peptides (CAPs) that exert antibiotic-like action against bacteria. These host-derived antibiotics kill susceptible bacteria by oxygen-independent mechanisms. Considerable interest in their activity has been generated in recent years due not only to their likely important role in innate host defense against infection, but also their possible use as therapeutic agents in treating infections caused by antibiotic-resistant pathogens. We have studied the antibacterial properties of human lysosomal cathepsin G (cat G). This highly cationic serine protease contains at least three antibacterial regions that by themselves can exert antibacterial action against Gram-negative bacteria, such as Pseudomonas aeruginosa. Only one of these peptides, defined by residues 117-136 of full-length cat G, has bactericidal action against Gram-positive pathogens, such as Staphylococcus aureus. Due to the broad-spectrum antibacterial action of this peptide, we have sought to define the amino acids within its primary sequence required for this activity and have developed variants with improved activity. This review emphasizes the importance of both cationicity and hydrophobicity as necessary characteristics for the antibacterial action of CAPs. It also proposes the strategy that naturally occurring large human CAPs can be dissected to smaller CAPs and then modified to enhance their activity in vitro. This approach could prove beneficial to those interested in developing antimicrobial peptides as therapeutic agents.
Collapse
Affiliation(s)
- W M Shafer
- Laboratories of Bacterial Pathogenesis, Research Service, The VA Medical Center, Decatur, GA 30033, USA.
| | | | | | | | | | | | | | | |
Collapse
|